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Hyperparathyroidism (HPT) is an overproduction of parathyroid hormone (PTH) by 
one or more of the parathyroid glands. Parathyroid hormone regulates the calcium 
and phosphate homeostasis in the body. Overproduction of PTH can have several 
causes. In primary hyperparathyroidism (pHPT) an intrinsic abnormal change has 
occurred, leading to an excess secretion of PTH in often one enlarged gland. Primary 
HPT is a common disorder affecting approximately one in 500 women and one in 
2000 men. It may lead to nephrolithiasis, osteoporosis, psychiatric symptoms, muscle 
weakness, constipation, excessive calcium deposits and reduced life expectancy if left 
untreated.  However 70-80% of the patients experience no obvious symptoms at the 
time of diagnosis. 1 Patients present with solitary glandular disease (solitary adenoma) 
in 87% of the cases. The remaining 13% present with multiglandular disease, including 
9% with  four gland hyperplasia, 3% with double adenomas and less than 1% with 
parathyroid cancer.2 Primary HPT can solely be cured by surgical resection of the 
hyperactive parathyroid gland(s).  
In secondary hyperparathyroidism (sHPT) an extrinsic persistent abnormal change 
has affected the calcium and phosphate homeostasis leading to stimulation of PTH 
production by all glands. The most common extrinsic factor is end-stage renal disease 
(ESRD). Secondary HPT can develop in early stages of chronic kidney disease and 
is present to some degree in all patients with ESRD. Low serum calcium, low active 
vitamin D and a high serum phosphate in these patients stimulate PTH secretion and 
synthesis, and induce parathyroid hyperplasia. Refractory sHPT is present when optimal 
medical and dietary treatment cannot control HPT. Chronic elevation of PTH in these 
patients has major consequences resulting in bone loss, fractures, soft tissue and organ 
calcification including vascular calcification, cardiovascular disease and increased 
mortality. Other causes of sHPT include osteomalacia, rickets, and malabsorption. 1,3
Medical treatment of sHPT consists of calcium supplementation, restricting phosphate 
intake and administration of phosphate binders and active vitamin D analogs. 
Calcimimetics are the latest medical treatment of sHPT. They modulate the calcium-
sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular 
calcium and thereby lowering PTH secretion from the parathyroid gland. Calcimimetics 
have proven to reduce serum  PTH, calcium and phosphate levels in dialysis patients 
with moderate to severe sHPT3, however a recent study reports no significant effect of 
calcimimetics on cardiovascular outcomes or death in patients with sHPT undergoing 
dialysis4. If medical treatment is not effective, parathyroidectomy (PTx) should be 
carried out. Incidence rates in different countries ranges from 0.5-1.5 per 100 patients 
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on dialysis per year. After long time hemodialysis rates of 10% after 10  years and 30% 
after 20 years are reported.5 
Tertiary hyperparathyroidism (tHPT) occurs after long-standing sHPT. Continuous 
extrinsic stimulation of the gland(s) has resulted in an intrinsic abnormal change 
leading to autonomous function.6  Usually tHPT refers to persisting HPT after renal 
kidney transplantation. In most patients renal transplant corrects the abnormal 
metabolism of calcium, phosphate and vitamin D. However, up to 5% of these patients 
will sustain elevated PTH levels by autonomously functioning parathyroid glands. 
Surgical intervention is  the preferred treatment option, although calcimimetics may 
have a role in medical treatment of these patients in the future.7 8  
Subtotal PTx with resection of 3.5 glands or total PTx with resection of all 4 glands 
combined with autotransplantation of 0.5 gland are considered standard surgical 
treatment in both refractory sHPT and tHPT. Currently, a trial comparing total PTx 
without autotransplantation or thymectomy to total PTx with autotransplantation and 
thymectomy is underway.9 Successful PTx dramatically reduces levels of PTH, calcium 
and phosphate levels, improves bone metabolism and decreases clinical symptoms 
and mortality.5
The position and number of parathyroid glands present can be at variance.  Most 
people have four parathyroid glands often located in the neck just behind the thyroid, 
two at each site. However 5-20% is found in an ectopic location elsewhere in the neck 
or mediastinum. In case of solitary adenoma, 1-3% of the glands are reported as ectopic. 
Supernumerary glands are seen in 5-6% of the patients. However in sHPT the reported 
incidence is higher ranging from 2-30% of which 80% is located in the thymus.2,10 
Because localization and number of glands is not determined, it can be difficult, even 
for experienced surgeons, to identify all of the hyperactive parathyroid glands. 
Before the 90’s of the last century the successful surgical localization of hyperactive 
parathyroid glands solely depended upon the surgeon’s experience. In the early 90’s 
the 99mTechnetium-hexakis-2-methoxy-isobutylisonitrile (99mTc-Sestamibi) scan became 
available and further developments included introduction of 99mTc-Sestamibi scintigraphy 
with single photon emission computed tomography (SPECT), ultrasonography, MRI 
and CT scan. Minimally invasive surgery was introduced in 1994 for patients with pHPT 
caused by solitary adenoma.11 It reduces the risk of recurrent nerve damage, operating 
time, length of hospital stay and costs.12 Ever since, the accurate preoperative localization 
of hyperactive parathyroid glands became more and more important. 
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Primary goal of imaging parathyroid glands is to localize the hyperactive gland(s) as 
preoperative workup. 99mTc-Sestamibi scintigraphy is generally the imaging modality 
of choice for preoperative localization. Identification of hyperactive parathyroids 
is based on a slower washout rate of Sestamibi from the hyperactive parathyroids 
than from thyroid tissue. 99mTc-Sestamibi scintigraphy is valued for its relatively high 
sensitivity and specificity. Several techniques are proposed to obtain an optimal result. 
A combination of 99mTc-Sestamibi dual phase technique with delayed SPECT and 
123I-subtraction may improve sensitivity, but is a time- and cost-consuming procedure. 
In chapter 2 the relative contributions of SPECT and 123I-subtraction in addition to 
planar 99mTc-Sestamibi scintigraphy were evaluated in both pHPT and sHPT. 
In radioguided PTx a gammaprobe is used for intraoperative nuclear mapping. Before 
surgery 99mTc-Sestamibi is injected in the patient which accumulates mainly in the 
hyperactive parathyroid gland over time. During surgery the probe will detect minute 
levels of radioactivity, so it can guide the surgeon. The parathyroid gland is frequently 
not easy to distinguish from other tissue like lymph nodes, thyroid tissue, fat tissue 
or thymus tissue. Murphy and Norman pointed out that if resected tissue contained 
more than 20% of background radioactivity in a patient with a positive  99mTc-Sestamibi 
scan result,  it proved to be parathyroid adenoma.13 The gammaprobe has been 
demonstrated useful in patients with pHPT. The role of radioguided surgery in sHPT is 
however unclear. We conducted a prospective study to evaluate the usefulness of  the 
gammaprobe during PTx for sHPT. The results are described in chapter 3.  
Although 99mTc-Sestamibi has been used for visualizing parathyroid tumors since 1989, 
the exact mechanism of retention in these tumors is unknown. Size is an important 
factor, but it is puzzling why some big tumors are not visualized and some small 
tumors are clearly visualized. Transmembrane proteins as P-glycoprotein (P-gp) and 
multidrug resistance-associated protein (MRP1) are known to transport 99mTc-Sestamibi 
over membranes and may determine the amount of retention of 99mTc-Sestamibi in 
and hence visualization of the parathyroid tumor. In chapter 4 the visualization of 
parathyroid tumors on 99mTc-Sestamibi scans, the in vivo uptake as measured by 
gammaprobe during PTx and the immunohistochemical presence of P-gp and MRP1 
in parathyroid tumors are evaluated. 
Because of the relatively short half-life of PTH (3-4 minutes), intraoperative measurements 
of PTH (ioPTH) can be used to confirm surgical cure after PTx. The basic principle is that 
once the hyperactive gland (or glands) has been resected, the measurable amount 
of PTH should decrease. Since its introduction in the early 1990’s14, it has become a 
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well-recognized predictor of surgical success in pHPT allowing minimal invasive PTx. 
However its role in surgery for sHPT and tHPT remains uncertain. In chapter 5 the 
results of ioPTH monitoring during PTx in sHPT and tHPT and analyzed and its clinical 
utility evaluated.
Secondary HPT is primarily managed by medical treatment like described before. If 
despite medical treatment PTH, calcium and phosphate levels cannot be controlled, 
surgical treatment is indicated. Patients with a high risk for refractory sHPT in the 
long run may benefit especially from early aggressive treatment. In chapter 6 early 
prognostic factors are described for the development of refractory sHPT needing 
surgical treatment in patients undergoing long-term renal dialysis. To identify these 
factors biochemical and treatment data were collected of patients at the start and 
during the first year of dialysis and related to the need for PTx during long-term follow-
up. 
Hyperparathyroidism is rarely based on parathyroid carcinoma. Commonly parathyroid 
carcinoma is diagnosed after surgery for pHPT, when the removed tumor shows 
malignant features at pathologic examination. Radical surgical resection is the only 
effective treatment modality, determining the prognosis of these patients. Therefore 
preoperative suspicion for parathyroid carcinoma is essential.  In chapter 7 the 
incidence, treatment, and relapse-free and disease-specific survival of patients with 
parathyroid carcinoma in The Netherlands is reported. The clinical presentation of 
parathyroid carcinoma patients is compared with a cohort of patients with solitary 
benign parathyroid disease to distinguish clinical features associated with an increased 
probability of parathyroid carcinoma.
In chapter 8 all results mentioned in this thesis are summarized. Furthermore, a general 
discussion,  future perspectives and recommendations for further research are given. 
Chapter 2
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Introduction: To find out if single-photon emission computed tomography (SPECT) 
and 123I-subtraction can enhance the findings of 99mTc-Sestamibi scintigraphy for the 
preoperative localization of parathyroid tumors.
Methods: Among the 111 consecutive patients who underwent preoperative planar 
99mTc-Sestamibi  scintigraphy for hyperparathyroidism (HPT), 64 underwent delayed 
SPECT, and 17 underwent 123I-subtraction. Two independent blinded experts scored 
the topographical localization, diagnostic confidence, and impact of each diagnostic 
modality on the surgical strategy. 
Results: For adenomas, 99mTc-Sestamibi  scintigraphy had a sensitivity of 77% with a 
positive predictive value (PPV) of 83%. SPECT did not affect the sensitivity or PPV, but 
it increased the diagnostic confidence and changed the surgical strategy in 21% of 
the patients. 123I-subtraction increased the sensitivity from 64% to 82%, but decreased 
the PPV from 88% to 82%. In hyperplastic glands, 99mTc-Sestamibi  scintigraphy had a 
sensitivity of 47% and a PPV of 95%. When 99mTc-Sestamibi  scintigraphy was combined 
with SPECT and 123I-subtraction, the results were 44%/10% and 52%/92%, respectively. 
Both SPECT and 123I-subtraction decreased the diagnostic confidence. 
Conclusion: Adding SPECT to 99mTc-Sestamibi  scintigraphy improved the surgical 
decision for parathyroid adenomas. The addition of 123I-subtraction was of limited 
value. For hyperplastic glands, 99mTc-Sestamibi  scintigraphy was relatively ineffective, 
even with the addition of SPECT or 123I-subtraction. 
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INTRODUCTION
Accurate preoperative localization of pathological parathyroid glands is important in 
the surgical treatment of hyperparathyroidism (HPT), to identify unusual or ectopic 
lesions and to provide information to determine if direct, minimally invasive surgery 
is appropriate.15 Currently, dual-phase 99mTc-Sestamibi scintigraphy is the imaging 
modality of choice. Identification is based on a slower washout rate of Sestamibi from 
the parathyroid than from thyroid tissues, although some parathyroid tumors may 
show a rapid tracer washout.16 Scintigraphy has a high sensitivity (90%) in detecting 
solitary adenomas in primary hyperparathyroidism (pHPT).2 In multiglandular disease, 
which is present in about 12% of patients with pHPT and is also found in patients 
with secondary (sHPT) or tertiary hyperparathyroidism (tHPT), the sensitivity for both 
adenomas and hyperplastic glands tends to be much lower (44%–54%).17-20
To improve the diagnostic performance of 99mTc-Sestamibi, single photon emission 
computed tomography (SPECT) is sometimes added to routine planar scans. SPECT 
improves contrast and provides a 3-dimensional visualization.21 This may increase 
diagnostic confidence and assist in the detection of ectopic localizations, possibly 
affecting the surgical strategy. Another method of enhancement is dual tracer 
subtraction scintigraphy using a thyroid specific 123I tracer subtracted from 99mTc-
Sestamibi , which is retained in both thyroid and parathyroid tissue. This method may 
enhance accuracy, especially in multiglandular disease, by reducing false positive (FP) 
results caused by thyroid nodules,22,23 and false negative (FN) results caused by early 
Sestamibi washout.24
We conducted this study to evaluate the surgical implications of adding SPECT and 
123I-subtraction to 99mTc-Sestamibi  scintigraphy to detect parathyroid tumors.
METHODS 
Patients 
Between 1994 and 2005, 111 consecutive patients with HPT were referred to our 
institute, a tertiary referral center in the North Netherlands, where planar 99mTc-
Sestamibi scintigraphy has been performed routinely since 1994, SPECT since 1998, 
and 123I-subtraction since 2002. All patients underwent PTx after 99mTc-Sestamibi 
scintigraphy. 
Ultimately, the exact location of the parathyroid tumors was determined during 
surgery and documented accordingly. Twelve (10.8%) patients were excluded from 
this study because of unsuccessful surgery, defined as an elevation of both PTH (>10 
pmol/l for pHPT and >20 pmol/l for sHPT) and calcium (>2.75 mmol/l) or the need for 
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calcium lowering dialysate in case of sHPT within 6 months postoperatively. Successful 
PTx was carried out in 99 patients: 29 men and 70 women with a mean age of 57 ± 14 
years. Sixty-six patients had pHPT, including 11 who needed reoperations for persistent 
or recurrent disease; 22 patients had sHPT, including 3 who needed reoperations; 7 
patients had tHPT; 3 patients had HPT as part of MEN syndrome; and 1 patient had HPT 
caused by long-term lithium use. Nodular thyroid disease was detected by palpation 
and ultrasonography in 25% of the patients. Parathyroid glands were defined as 
abnormal if they weighed more than 55 mg or their largest diameter exceeded 7 
mm at surgical or pathologic examination.25 If hypercellularity was seen in all excised 
glands, they were considered to be hyperplastic. If hypercellularity was documented in 
≤2 glands found in the presence of one or more normal appearing glands, they were 
considered to be adenomas. If there was any doubt, the original histological slides 
were retrieved and re-evaluated by an experienced pathologist. 
Scan Protocol 
Planar scintigraphy was evaluated in all of the 99 patients, additional SPECT was 
evaluated in 58 of these patients, and 123I-subtraction was evaluated in 16. 99mTc-
Sestamibi scintigraphy was performed using a Siemens Multispect2 gamma camera 
(Hoffmann Estates, IL, USA) with a low-energy high-resolution collimator (99mTc, 140 
keV, 15%). Ten minutes after the intravenous (i.v.) injection of 400 MBq 99mTc-Sestamibi, 
early static images were obtained with an acquisition time of 10 min. SPECT images 
were obtained 90 min after the i.v. injection of 99mTc-Sestamibi  (2 × 32 views during 
60 s), followed by late static images 120 min after the i.v. injection of 99mTc-Sestamibi 
with an acquisition time of 10 min. Next, a static image was taken 120 min after the 
patient swallowed 11 MBq 123I. 123I images were subtracted from the early 99mTc images 
using a variable multiplication factor for 123I images on the basis of a visual inspection 
without creating imaging artifacts. Marking of the jugular notch and shoulders and 
careful laser-based repositioning were used to minimize subtraction artifacts caused 
by movement of the patient.
Image Interpretations 
Images were visually evaluated by two independent experienced nuclear medicine 
physicians, who were blinded to the clinical outcome or results of other localization 
studies. A consensus was reached if there was disagreement. Early- and late-planar 
images were analyzed first, followed by SPECT images, and finally, 123I-subtraction 
images, to determine the relative contributions of SPECT and 123I-subtraction. A positive 
finding was defined as a relative increase in 99mTc-Sestamibi  uptake in the neck area 
or mediastinum, which could not be attributed to normal physiologic uptake. The 
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diagnostic confidence of each suspected lesion was categorized as high, moderate, or 
low, and the detected lesion was drawn on a planar anterior image of the neck (figure 
1A). Lesions on SPECT were also drawn in the sagittal SPECT plane (figure 1B). Regions 
were chosen according to surgical relevance on the basis of the different dissection 
planes where parathyroid tissue is found. 
Figure 1.  Coronal (A) and sagittal (B) view of the regions used for topographical localization: 
1) retropharyngeal region, 2) region directly lateral or posterior of the thyroid, 3) tongue of the 
thymus, 4) mediastinal thymus, 5) mediastinal region underneath v.brachiocephalica, 6) dorsal 
or caudal tracheoesophageal region, 7) paravertebral region.56
The preoperative scintigraphic location of the lesions was compared with the 
surgically determined location. Results were considered true positive (TP) or false 
negative (FN) when enlarged parathyroid glands were detected correctly or incorrectly, 
during surgery in one of the regions, irrespective of the assigned diagnostic confidence. 
Scintigraphic lesions were considered false positive (FP) when no abnormal glands 
were found in the previously indicated region. Analysis was based on individual lesions 
and sensitivity, defined as TP/(TP + FN). The positive predictive value (PPV), defined as 
TP/(TP + FP), was calculated because the PPV is important from a surgical point of view.
The effect of the scintigraphic results on the surgical strategy; namely, minimally 
invasive parathyroidectomy (MIP) versus conventional bilateral neck exploration, was 
determined only in patients with pHPT. Scoring was based on the consensus of two 
experienced parathyroid surgeons, after consideration of the imaging information of 
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planar, planar + SPECT, or planar + SPECT + subtraction. MIP is a limited unilateral 
approach to a localized hyperactive parathyroid gland through a 2-cm skin incision 
without visualization of the remaining parathyroid glands. With MIP, there is a risk 
of missing an adenoma and this procedure was advised only if imaging showed a 
solitary adenoma with moderate to high diagnostic confidence. Conventional  neck 
exploration with inspection of all parathyroid glands was performed in all other 
patients.
Statistical Analysis 
Student’s t test and the Chi-square test were applied and a P value of less than 0.05 was 
considered to be significant. Results are expressed as means ±2 SD throughout this 
study. Topographic localizations and diagnostic confidence scoring by the two readers 
were analyzed for interobserver agreement, and κ-statistics were computed.26
RESULTS 
Interobserver Agreement 
The interobserver agreement for diagnostic confidence and topographic localizations 
ranged from 64% to 86% with a κ of 0.50–0.77 representing good agreement. Except 
for the localization of tumors detected after the addition of subtraction images, 77% 
agreement was reached with κ (0.41) representing good agreement (0.40–0.80). 
Detection of Adenomas 
Of the 66 patients with pHPT, 63 (95%) underwent removal of a solitary adenoma. 
These adenomas were detected during preoperative 99mTc-Sestamibi  scintigraphy in 
50 patients, giving a sensitivity of 79% and a PPV of 88%. Two adenomas were found in 
three patients, but only the largest one was detected during preoperative scintigraphy. 
Adenomas were also present in five of the patients with tHPT and in two of those with 
MEN syndrome. The total adenoma group consisted of 77 adenomas in 73 patients, 
59 of which were detected during planar scintigraphy, yielding an overall sensitivity 
of 77% and a PPV of 83%. In the 59 correctly detected adenomas, the diagnostic 
confidence on planar images was categorized as low in 8%, moderate in 40%, and 
high in 51%. When we compared the detection of adenomas between early and late 
images, 11 (18.6%) adenomas were identified only on early images, 14 (23.7%) only on 
late images, and 34 (57.6%) on both. 
Of the 73 patients with adenomas, 44 underwent SPECT, which did not affect 
the sensitivity or PPV in the detection of adenomas (figure 2A). SPECT resulted in the 
detection of two additional adenomas after planar scans, but two other adenomas were 
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incorrectly considered to be absent after SPECT. Thus, SPECT increased the diagnostic 
confidence in 21% of the adenomas, but it decreased the reading confidence in 9%. 
As SPECT provides a three-dimensional image, its contribution to the localization 
of ectopic parathyroid glands was analyzed separately. Of the 11 ectopic adenomas 
in this study, 7 were dorsocaudal of the tracheoesophageal region, 1 was located in 
the paravertebral region, and 3 were located in the thymus. SPECT was performed 
on 8 of these 11 patients. Although SPECT provided no further information on the 
planar images to aid in detecting three thymic adenomas, it proved very useful in 
detecting three adenomas in the dorsal tracheoesophageal region. However, one 
tracheoesophageal adenoma and one paravertebral adenoma were not localized 
correctly in the sagittal plane. 
We were able to evaluate the impact of SPECT on the surgical strategy in 38 patients 
with pHPT. In 11 (11/38; 29%) patients, additional topographic information or increased 
diagnostic confidence after SPECT changed the surgical strategy. Minimally invasive 
surgery was recommended for five patients, but was not advised for three, because 
SPECT showed an ectopic dorsal location. In three other patients decision changes 
were based on FP or FN SPECT results. Therefore, the change in surgical strategy on the 
basis of SPECT findings proved incorrect in three (3/38; 8%) and correct in eight (8/38; 
21%) patients. 
Figure 2. Sensitivity, positive predictive value (PPV), and diagnostic confidence for adenomas 
after planar images with the addition of single photon emission computed tomography (SPECT) 
in 44 patients (A) and subtraction images in a subgroup of 10 of these patients (B). The level of 
diagnostic confidence is given only for correctly detected glands. N = number of glands; PPV = 
positive predictive value; pl = planar; sp = SPECT; su = 123I subtraction.
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123I-subtraction images were added to the planar and SPECT images in a subgroup of 
10 patients with adenomas. This increased sensitivity from 63% to 82% by showing 
two additional adenomas. Despite this increase, the PPV decreased, because there 
were more FP findings (figure 2B). 123I-subtraction images proved helpful in 1 of the 
10 patients, and changed the surgical strategy by filtering out a FP lesion detected on 
planar and SPECT images. The increase in sensitivity, the decrease in PPV, and the lower 
interobserver agreement for topographical localization after subtraction, is largely 
explained by the imaging results of two patients. In both patients, planar and SPECT 
studies were negative, whereas subtraction revealed a TP and a FP lesion (figure 3). 
Figure 3. Early planar (A), late planar (B), and SPECT images (not shown) were read as negative 
in a patient with primary hyperparathyroidism (pHPT).  On retrospective evaluation, two lesions 
were seen on the early image (arrows). Subtraction of 123I (C) from the early planar image (D), 
showed two lesions clearly. One was true positive (TP) and one was false positive (FP), illustrating 
the mixed effect of subtraction. 
Detection of Hyperplastic Glands 
We performed subtotal PTx for sHPT in 22 patients, 19 of whom were operated on 
for the first time. Preoperative 99mTc-Sestamibi  scintigraphy localized 36 of the 68 
hyperplastic glands removed from these patients, yielding a sensitivity of 52% and a 
PPV of 95%. In three patients who underwent reoperation for persistent sHPT, one or 
two hyperplastic glands were removed. A single gland was detected by preoperative 
scintigraphy in all three patients, but a second residual gland was missed in two of 
these patients. Hyperplastic glands were also found in two patients with tHPT, one 
with MEN syndrome, and the one with HPT caused by long-term lithium use. There 
were a total of 89 hyperplastic glands in 26 patients. Planar scintigraphy resulted in 
correct localization in 42 of these glands, yielding a sensitivity of 47%, with a PPV of 
95%. In these 42 correctly localized glands, the examiners scored their diagnostic 
confidence on  the basis of planar images as low in 17%, moderate in 60%, and high in 
24%. On early and late images, 9 (21%) glands were detected only on early images, 15 
(36%) only on late images, and 18 (43%) on both. The early- and late-detection rates for 
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adenomas and hyperplastic glands did not differ. 
Single photon emission computed tomography, which was done for 14 of the 26 
patients with hyperplastic glands, decreased rather than increased sensitivity (figure 
4A). After the planar scans, SPECT images resulted in the identification of three (6%) 
extra hyperplastic glands, but at least eight (16%) were incorrectly considered absent 
after SPECT. Diagnostic confidence increased in 22% of the glands, but decreased 
in 26% after SPECT. In total, seven ectopic hyperplastic glands were found in seven 
patients: four in the thymus, one dorsal of the tracheoesophageal region, and two 
inside the thyroid. SPECT resulted in the localization of two thymic glands, but failed 
to correctly localize two glands inside the thyroid. The other three glands were not 
detected at all.
The subsequent addition of subtraction images in a subgroup of six patients with 
hyperplastic glands increased the sensitivity by localizing an extra hyperplastic gland 
(figure 4B). However, diagnostic confidence decreased and one extra FP gland was 
detected. 
Figure 4. Sensitivity, PPV, and diagnostic confidence for hyperplastic glands after planar images 
with the addition of SPECT in 14 patients (A) and subtraction images in a subgroup of 6 of these 
patients (B). The level of diagnostic confidence is given only for correctly detected glands. N = 
number of glands; PPV = positive predictive value; pl = planar; sp = SPECT; su = 123I subtraction.
Gland Weight 
The mean weight of the adenomas was 1442 ± 1635 mg, whereas that of the 
hyperplastic glands was 784 ± 665 mg (P < 0.05). The weights of the correctly and 
incorrectly detected glands are shown in table 1. The five glands detected on SPECT, 
but not on planar images, ranged in weight from 960 mg to 6000 mg, which was not 
different from that of the glands detected on both images. 
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Table 1: Weight of glands according to true positive or false negative findings.
TP FN P
Planar
WA 1295 ± 795 * 531 ± 659* <0.01*
WH 990 ± 666 474 ± 543 <0.01
Planar + SPECT
WA 1853 ± 2068 356 ± 236 <0.01
WH 133± 629 359 +182 <0.01
Planar + SPECT
+ 123I-subtraction
WA 1100 ± 710 350 ± 354 0.19
WH 1085 ± 640 393 ± 101 0.11
FN = false negative glands; P = P value, TP = true positive glands, WA = weight of adenomas, WH = weight 
of hyperplastic glands; SPECT = single-photon emission computed tomography. *Analysis was done after 
the exclusion of outliers
DISCUSSION 
About 12% of patients with pHPT have multiglandular disease.2 The preoperative 
localization of abnormal parathyroid glands is important for determining if MIP is 
appropriate.15 The sensitivity of 77% in the topographical localization of pHPT with 
dual-phase scintigraphy in our series is in accordance with the reported sensitivities of 
53%–100% in a recent systematic meta-analysis.27 Like Staudenherz et al.,28 we found 
that adding delayed SPECT did not increase sensitivity. However, other investigators 
described an increase in sensitivity from 87% to 95%.29 SPECT provides the surgeon 
with a 3-dimensional image of the location of adenomas, especially dorsal ectopic 
adenomas, and enhances the diagnostic interpretations by nuclear physicians.30 On 
the basis of our interpretation of the SPECT images, we changed the surgical strategy 
for 21% of our patients with pHPT, allowing minimally invasive surgery to be performed 
more safely. 
Delayed SPECT has lower sensitivity (55%–91%)21,31,32 than early SPECT (91%–
96%),33,34 which was reported to be superior because a limited number of adenomas 
showed retention of Sestamibi.33 We observed retention on late-planar images in 
62% of the adenomas in this series. However, in 14% of the adenomas, retention was 
observed on early images 20 min after injection, but not on late images 120 min after 
injection. However, as 80% of these adenomas were detected on delayed SPECT, the 
optimal time for SPECT with the highest sensitivity and a good discrimination of the 
adenoma from the thyroid has yet to be determined. 
The sensitivity for detecting adenomas improved by adding 123I-subtraction 
imaging, but at the expense of PPV, and the diagnostic confidence was not improved. 
123I-subtraction imaging had a beneficial impact on the surgical strategy in only 10% 
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of the patients. Moreover, there was poor interobserver agreement, as lesions with 
a low signal were difficult to differentiate from background noise, leading to FP or 
FN results. The supposed advantage of 123I-subtraction imaging is that it prevents 
FP findings by Sestamibi uptake in the thyroid nodules.15,30 123I-subtraction imaging 
corrected FP findings in one of our patients, but it failed in another patient with a 
thyroid adenoma. Gallowitsch et al.35 reported more FP findings of adenomas with 
subtraction scintigraphy, without any difference in sensitivity (87%), than with SPECT. 
Three other studies compared dual-phase with subtraction scintigraphy, and although 
the sensitivities for dual phase (62%–79%) and subtraction (72%–94%) ranged widely, 
subtraction was found to be superior to dual-phase scintigraphy in all the three 
studies.30,36,37 Hindie et al.37 used the subtraction technique with simultaneous double-
window acquisition and found that subtraction had higher sensitivity and a lower FP 
rate (3%) than the dual-phase technique. Simultaneous double-window acquisition 
prevents motion artifacts, which may result in FP findings, and it also takes less time. 
Thus, it may be a good alternative, although the problems created by the cross-talk of 
radioisotopes should be solved.38 Careful reading of the images in this series showed 
that motion artifacts were not the cause of our two FP findings. We found that the 
subtraction technique is not contributory in general, but it can be helpful, particularly 
for patients with negative planar and SPECT studies. 
Multiglandular disease in patients with pHPT, as diagnosed in three of our patients 
who had double adenomas, was not recognized by any of the techniques. Only the 
largest of the double adenomas was detected by scintigraphy. A wide range (8%–80%) 
of sensitivities using several techniques for the detection of multiglandular disease in 
pHPT has been reported.21,39-42 Hindie et al.43 even reported 100% (9/9) sensitivity using 
the subtraction technique, but they achieved a PPV of only 50% (9/18). Differentiating 
multi- from uniglandular disease is important to determine if minimally invasive surgery 
can be performed safely. As yet, there seems to be no reliable imaging technique that 
can identify multiglandular disease in patients with pHPT. Other methods, including 
intraoperative PTH measurements, are necessary to exclude multiglandular disease.44
Patients with sHPT usually present with hyperplasia of all glands and preoperative 
localization remains questionable because of the low sensitivity of most imaging 
modalities and the need for bilateral exposure. The main reason for unsuccessful 
surgery, as seen in 10%–30% of these patients, is incomplete localization of all 
glands.10 Therefore, we must evaluate all the available imaging modalities thoroughly. 
According to previous studies, dual-phase scintigraphy yielded a low sensitivity 
for hyperplastic glands.17-20 However, SPECT did not improve the sensitivity and 
delayed SPECT even reduced the sensitivity (54% vs. 44%), which may be attributed 
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to the spatial resolution limits of SPECT and the low signal in some glands against 
background noise. Gallowitsch et al.35 reported lower sensitivity (38%) with dual-phase 
scintigraphy, but higher sensitivity with SPECT (62%). SPECT increased the diagnostic 
confidence of some hyperplastic glands detected on both planar and SPECT images. 
This may be important in high-risk patients, but it has no impact on the initial surgical 
treatment. In hyperplastic parathyroid glands, good results have been reported with 
subtraction techniques using double-window acquisition for planar or SPECT imaging, 
leading to high sensitivities ranging from 77%–91% in small groups.22,23,38 However, the 
subtraction images in our series did not increase sensitivity remarkably. Conversely, the 
images were more confusing than helpful, considering the lower confidence scores 
and interobserver agreement after the addition of subtraction images. This was not 
surprising because many of these glands have a low signal near the limit of detection. 
It is unknown why hyperplastic glands trigger weaker signals and lower sensitivities 
than adenomas, but several mechanisms have been proposed. First, the uptake might 
be limited by the size of the tumor. In the present series, hyperplastic glands were 
smaller than adenomas and our data confirm the association between size and the 
detection of parathyroid tumors by 99MTc-Sestamibi scintigraphy.22,36 Second, the 
difference in uptake of Sestamibi may be related to the distribution of chief and oxyphil 
cells in parathyroid tumors. Oxyphil cells are richer in mitochondria that accumulate 
Sestamibi. Third, the difference may be related to the expression of P-glycoprotein 
on the membrane of parathyroid cells responsible for the fast washout of Sestamibi 
by pumping it out of the cell.45 Hyperplastic glands are reported to have a faster 
washout than adenomas, although the number of hyperplastic glands detected solely 
on early scan in the present study was 9%, which was not remarkably different from 
that of adenomas. Subtraction techniques are recommended to detect glands with a 
fast washout of activity.30 However, a higher rate of detection of hyperplastic glands 
after the addition of subtraction images was not observed in this study. Although 
fast washout might have occurred before early static imaging, it is more likely that 
the smaller size of the hyperplastic glands and their lower uptake of Sestamibi were 
responsible for their low sensitivity. 
Neither SPECT nor 123I-subtraction technique improved the low sensitivity of 
planar 99mTc-Sestamibi  scintigraphy in detecting hyperplastic glands, which raises 
the question: Is there any use for preoperative scintigraphy in patients undergoing 
initial surgery for sHPT? As stated earlier, bilateral neck exploration should be done 
in all patients undergoing initial surgery. Preoperative scintigraphy can have surgical 
implications if ectopic or supernumerary glands are detected.22 In our series, the only 
ectopic glands detected were localized in the thymus. As this is a common location 
for ectopic or supernumerary glands in patients with secondary disease, it is advisable 
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to perform transcervical thymectomy in all these patients.46 A second surgical benefit 
of preoperative scintigraphy is that it may supply functional information. Sestamibi 
uptake reflects the degree of suppressibility and autonomy.47 Therefore, glands 
with low uptake may have low probability of recurrence and should be chosen for 
autoimplantation.46 With the techniques currently available, preoperative Sestamibi 
scintigraphy is of limited value for localizing parathyroid glands in patients undergoing 
initial surgery for sHPT. However, in patients with persistent or recurrent sHPT it remains 
useful to detect residual and often ectopic glands.10,19
Recently, it was suggested that patients with tHPT could be treated by excising 
one or two enlarged glands if the remaining glands were not enlarged.48 We found 
adenomas in five of seven patients with tHPT, four of whom had a solitary adenoma, 
which was correctly localized as such. In one patient, scintigraphy showed a solitary 
lesion, but four enlarged glands were found during surgery. Therefore, the value of 
scintigraphy in selecting candidates for limited resection of tHPT remains questionable.
Sestamibi scintigraphy is generally recommended as the initial imaging modality 
for patients with HPT. It is especially useful to detect a solitary adenoma in patients 
with pHPT, with high sensitivity, and to detect ectopic hyperplasia in patients with 
sHPT or tHPT. Other imaging modalities used to detect parathyroid tumors include 
ultrasonography, CT, and MRI. Ultrasound is operator-dependent and a wide range of 
sensitivities have been reported (44%– 87%).49 Moreover, it is relatively ineffective for 
localizing ectopic glands with dorsal or mediastinal localization. A few studies have 
reported that CT has 40%–88% sensitivity, with good anatomic information.50 MRI 
has an overall sensitivity of 50%–88%, and is especially sensitive for demonstrating 
mediastinal and intrathymic ectopic glands.51-53 New techniques such as CT-Sestamibi 
image fusion are currently being evaluated and appear to be superior, especially for 
locating ectopic glands.54,55 However, scintigraphy is readily available and reliable. For 
patients with pHPT, we recommend Sestamibi planar scintigraphy in combination 
with SPECT to determine if minimally invasive surgery is indicated. Institutions with 
excellent ultrasound equipment might consider performing additional SPECT only 
when the ultrasound findings are negative. For patients with sHPT, scintigraphy is 
not recommended before initial surgery, although it can be valuable before revision 
surgery. For both pHPT and sHPT, other imaging modalities are recommended when 




Our findings show that SPECT can be valuable in addition to planar 99mTc-Sestamibi 
scintigraphy for detecting parathyroid adenomas in pHPT, by localizing ectopic 
glands, improving diagnostic confidence and the surgical strategy. We found 99mTc-
Sestamibi/123I-subtraction to be of no additional value in pHPT, although it might be 
useful if the planar and SPECT findings are negative. For hyperplastic glands in patients 
with sHPT or tHPT, planar 99mTc-Sestamibi  scintigraphy before the initial surgery is of 
limited value with minimal surgical implications, and it is not improved by SPECT or 
123I-subtraction. 
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Introduction: In primary hyperparathyroidism (pHPT) the gammaprobe is effective, but 
its role in secondary hyperparathyroidism (sHPT) is unclear. We investigated the utility 
of the probe in the surgical management of sHPT and tertiary hyperparathyroidism 
(tHPT). 
Methods: The value of the probe in guiding resection of parathyroids was determined 
prospectively in 29 patients with sHPT or tHPT. Resected tissue with radioactivity of 
greater than 20% as compared with the wound bed was considered a hyperactive 
parathyroid and was confirmed histologically. 
Results: The probe was helpful in guiding resection of 13% of the hyperplastic glands, 
including ectopic glands and those not detected preoperatively. The gammaprobe 
confirmed the presence of hyperactive parathyroid after resection with a sensitivity 
and specificity of 97% and 92%, respectively. 
Conclusion: The probe is particularly useful in confirming the presence of hyperactive 
parathyroid after resection. It also is useful in identifying ectopic localization, but its 
value is limited in guiding surgery for secondary or tertiary disease.
  Intraoperative gammaprobe
31
INTRODUCTION
Secondary HPT is present to some extent in all patients with chronic renal failure. Low 
serum calcium and vitamin D levels with high serum phosphate levels in renal failure 
stimulate parathyroid hormone (PTH) secretion and induce parathyroid hyperplasia. 
Serious complications including renal osteodystrophy and vascular calcifications lead 
to increased cardiovascular morbidity and mortality.57,58
Parathyroidectomy (PTx) is required if sHPT (sHPT) cannot be controlled by optimal 
medical and dietary treatment. Surgery comprises bilateral exploration of the neck to 
identify all parathyroid glands, followed by subtotal resection or total resection with 
parathyroid autotransplantation. In comparison with surgery for pHPT, the rate of 
persistent or recurrent disease is high (3%–12%). Treatment failure often is related to 
incomplete identification of all parathyroid glands. If less than 3 glands are removed, 
failure rates of 34% to 72% are reported.10,59 Reoperations also have a higher failure rate 
(11%–27%) with more complications and a longer surgical time.10,60
In minimally invasive surgery for pHPT, the gammaprobe has been shown to be 
useful in facilitating the localization of a solitary adenoma after preoperative injection 
of 99mTc-sestamibi.61 Moreover, the probe also confirms the presence of an adenoma 
if radioactive counts in the resected tissue are greater than 20% of the background 
counts in the wound bed, obviating the use of intraoperative frozen-section analysis.13 
Generally, radioguided surgery using the gammaprobe is considered less valuable in 
patients with sHPT. First of all, limited surgery is not feasible if all parathyroids have 
to be identified. Second, the sensitivity of preoperative 99mTc-sestamibi scintigraphy 
in localizing hyperplastic glands in sHPT is considerably lower in comparison with 
adenoma in primary disease (44%–54% vs. 90%).2,17-20 However, the gammaprobe may 
be valuable in decreasing the rate of surgical failure owing to insufficient identification 
of all hyperplastic glands and confirming the presence of hyperactive parathyroid 
glands after resection.
In this study we determined the utility of the gammaprobe in intraoperative 
nuclear guiding missing parathyroids and in confirming the presence of hyperactive 
parathyroid glands after resection in sHPT.
METHODS
Patients
Thirty-one patients with sHPT or tHPT were referred for PTx to our surgical department 
between January 2002 and January 2006. Two patients did not receive preoperative 
99mTc-sestamibi intravenously because of logistic problems. Twenty-nine patients who 
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underwent PTx using the gammaprobe were included in this study. All data were 
recorded prospectively with a minimal follow-up period of 12 months, except for 1 
patient who died 7 months postoperatively from causes not related to the parathyroid 
surgery.
The study group consisted of 25 patients with sHPT and 4 patients with tHPT. 
At preoperative examination consisting of palpation and echographic examination 
the thyroid had a nodular appearance in 8 of the 29 patients (28%). Two of these 25 
patients with sHPT presented with recurrent disease 2 to 5 years after primary PTx. 
The patients with tertiary disease presented with hyperparathyroidism 4 to 15 months 
after renal transplantation. The indication for surgery was persistent increased PTH 
(>20 pmol/L) despite optimal conservative treatment, in combination with either 
renal osteodystrophy, persistent hypocalcaemia (>2.75 mmol/L or need for calcium-
lowering dialysate), severe pruritus, serum calcium-phosphate product greater than 5 
mmol2/L2, and progressive extraskeletal calcification with pain, fractures, deformities, 
or calciphylaxis, as described by Malberti et al.62 Unsuccessful surgery leading to 
persistent hyperparathyroidism was defined as a serum calcium level greater than 2.75 
mmol/L in combination with a PTH level greater than 20 pmol/L within 6 months after 
surgery or the need for decreasing calcium in the dialysate in combination with a PTH 
level greater than 20 pmol/L. Any repeat increase of the serum PTH and calcium or 
phosphate levels refractory to treatment after this period was considered recurrent 
disease.48,63,64 Intact PTH level was measured with the ILMA advantage (Nichols) intact 
PTH assay.
Preoperative scintigraphy
A Siemens Multispect-2 gamma camera (Siemens, Chicago, IL, USA) was used for all 
scintigraphic studies with a low-energy, high-resolution collimator (99MTc, 140 keV, 15%) 
and was available in 26 of 29 patients. Ten minutes after intravenous injection of 400 
MBq 99mTc-sestamibi early static images were obtained with an acquisition time of 10 
minutes. Single-photon emission computerized tomography images were obtained 
90 minutes after injection of 99mTc-sestamibi (2 x 32 views during 60 sec) followed by 
late static images 120 minutes after injection with an acquisition time of 10 minutes. 
A positive finding was defined as a focus of 99mTc-sestamibi uptake in the neck area or 
mediastinum that could not be attributed to normal physiologic uptake. Scintigraphic 
location of lesions was compared with the surgically determined location. Glands 
found in the region directly lateral or posterior of the thyroid were defined as eutopic. 
Glands found outside this region in the retropharyngeal region, thymus, mediastinal 
region underneath the vena brachiocephalica, paravertebral region, or dorsocaudal 
tracheoesophageal region were defined as ectopic.
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Surgical treatment
Total PTx was performed with auto-implantation of a partial parathyroid in the 
sternocleidomastoid muscle. All patients underwent surgery by the same experienced 
surgeon, who was aware of the preoperative localization results. In all patients 400 
MBq 99mTc-sestamibi was administered intravenously 1 to 2 hours before incision. 
After a conventional approach, the thyroid was mobilized and the area dorsal of the 
thyroid was inspected visually. If enlarged parathyroids were identified during primary 
inspection without the use of the gammaprobe, the surgeon judged that the probe 
had not facilitated the localization of the glands. If enlarged parathyroids were not 
recognized during primary inspection, the gammaprobe (Neoprobe 2000; Neoprobe 
Corp., Dublin OH, USA) was used for guidance of missing parathyroids. An area with a 
signal higher than the surrounding area was examined thoroughly by the surgeon. If 
the signal of the gammaprobe led to identification of a suspected gland, the surgeon 
judged as objectively as possible that the probe had facilitated the localization of the 
gland. The exact localization of the suspected lesions was noted conscientiously on an 
anatomic drawing according to a protocol.
The value of the gammaprobe in confirming the presence of hyperactive 
parathyroid gland was determined by measuring radioactive counts after resection of 
suspected lesions. Relative radioactivity defined as radioactivity ex vivo divided by the 
radioactivity in the wound bed (counts per second) was assessed. Excised tissue with a 
relative radioactivity of at least 20% was defined as a parathyroid tumor, as suggested 
by Murphy and Norman.13 The relative radioactivity of excised tissues (>20% or ≤20%) 
was compared with the gold standard of histologic examination.
Pathologic examination
Tissue was considered to be a parathyroid tumor when the weight exceeded 55 
mg.25 Glands were defined as an adenoma if hypercellularity was seen in 2 or fewer 
glands in the presence of 1 or more normal-appearing glands or in combination with 
normalization of PTH and calcium levels during the 6 months after surgery. Glands 
were defined as hyperplastic if hypercellularity was seen in 3 or more excised glands 
of 1 patient, as recently reported in a pathologic review on histologic examination of 
parathyroid tissue.65
Statistical analysis
Statistical analysis was performed using the Student t test and linear regression analysis 
as appropriate (a 2-sided P value <.05 was considered significant). Data are presented 





Preoperative scintigraphy was performed in 26 of 29 patients. In total, 38 of the 93 
hyperplastic glands found during surgery in these 26 patients were visualized on the 
preoperative scan, leading to a sensitivity of 41% as based on individual lesion analysis 
for topographic localization. In 2 patients the preoperative scan was negative although 
8 glands were removed during surgery. In 24 patients at least 1 gland was visualized 
preoperatively. Four of 8 ectopic glands were localized correctly.
Surgical results
Surgery was successful in 26 of 29 patients (90%). Preoperative and postoperative PTH 
values are given in table 1. In 27 patients who underwent primary surgery for sHPT, the 
success rate was 89%. In 20 patients, 4 hyperplastic parathyroid glands were identified 
and removed and in 1 patient even 5 hyperplastic glands were resected. In 5 patients 
3 glands were removed, however, in 2 of these 5 patients surgery was unsuccessful. In 
1 patient 2 glands were removed, resulting in persistent hyperparathyroidism as well.
Two patients who presented with recurrent disease underwent bilateral exploration 
with PTx and auto-implantation of a partial parathyroid gland. In the first patient 2 
residual hyperplastic glands were removed. In the second patient with recurrent 
disease, hyperplastic parathyroid tissue was not identified in resected tissues, although 
the PTH level stayed low (2 pmol/L) for at least 12 months after resection.
Adding these patients together, a total of 104 parathyroid tumors were removed. 
Most glands were identified in eutopic localizations directly lateral or posterior of the 
thyroid (90%). Ten glands were found in ectopic localizations (10%); 7 glands in the 
tongue of the thymus, 1 intrathyroidal, and 1 in the dorsocaudal para-esophageal 
region. All parathyroid tumors were hyperplastic with a mean weight of 906 ± 729 mg, 
excluding the weight of auto-implanted glands that were usually smaller.
Table 1:  Pre- and postoperative PTH values
Pre-PTx 6 m post- PTx 12 m post-PTx
PTH (pmol/l) 113 ± 61 5.0 ± 5.1 5,8 ± 4.5
PTH values are given for patients with successful surgery (n = 26). 
PTx=parathyroidectomy; m=months
  
Value of gammaprobe in guiding resection
The probe facilitated in localizing 13% (14 of 104) of the hyperplastic glands. In 9 of 
29 patients (31%) the probe facilitated in localizing at least 1 gland. The probe was 
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helpful in localizing 4 of 10 ectopic hyperplastic glands. The probe was helpful in 
localizing 8 hyperplastic glands that were anatomically incorrect (n = 1) or not at all 
(n = 7) detected on preoperative scintigraphy. Four of these hyperplastic glands were 
located ectopically.
Value of gammaprobe in affirming the presence of hyperactive parathyroid 
glands after resection
The relative radioactivity of hyperplastic glands was 90% ± 61% (figure 1). All hyperplastic 
glands measured a relative radioactivity of greater than 20% except for 3 glands. These 
findings led to a sensitivity of 97% (101 of 104) for hyperplastic glands in confirming the 
presence of hyperactive parathyroid glands after resection. The 3 glands with a relative 
radioactivity of less than 20% weighed less than 200 mg and were not detected on 
preoperative scintigraphy. Correlating the gland weight to the relative radioactivity, 
there was a significant relation for hyperplastic glands (R2 = .42, P < .001). There were 
2 false-positive findings with the probe of non-parathyroid tissue measuring greater 
than 20% relative radioactivity, resulting in a false-positive rate of 2% and specificity 
of 92% in secondary disease (figure 1). Both false positive findings were encountered 
in the same patient. They consisted of nodular thyroid tissues weighing 100 and 200 
mg with microscopic signs of inflammation. Measurements with the intraoperative 
gammaprobe using the 20% rule were more effective in identifying hyperactive 
parathyroid tumors compared with preoperative 99mTc-sestamibi scintigraphy as 
shown in figure 2. However, parathyroid tumors identified with both instruments had 
a higher relative radioactivity (122% ± 75% vs. 70% ± 42%; P < .001).
 
Figure 1 Relative radioactivity of hyperplastic 
parathyroid (A), thyroid (B), lymphoid (C), 
fat (D) and normal parathyroid tissues (E). 
Straight line represents the mean value 





Figure 2 Intraoperative relative radioactivity per 
gland according to preoperative 99mTc-Sestamibi 
imaging results in 26 patients. Straight lines 
represent the mean value of the group. Dotted 
line represents 20% relative radioactivity.  TP = 
true positive scintigraphic findings; FN = false 
negative scintigraphic findings. 
DISCUSSION
The role of the gammaprobe during PTx for sHPT has not yet been determined. The 
gammaprobe can be useful and affect the surgical strategy in 2 ways. The probe could 
confirm the presence of hyperplastic parathyroids after resection with a high sensitivity 
(97%). Although the probe was less valuable in guiding the resection in sHPT, it was 
helpful in localizing ectopic hyperplastic glands, even if they were not detected on 
preoperative scintigraphy.
Previous studies have shown that hyperplastic glands in sHPT can be confirmed 
intraoperatively as parathyroid tumor, by measuring greater than 20% radioactivity 
in the resected lesion as compared with the background.66-68 In contrast, 2 studies 
reported a low relative radioactivity (8%-11%) for hyperplastic glands in patients with 
pHPT.13,69 The fact that those hyperplastic glands were found in patients with primary 
instead of secondary disease does not clearly explain the difference in results because in 
both types of disease the glands are hyperactive with a low sensitivity on preoperative 
scintigraphy. However, in both studies the delay between 99mTc-sestamibi injection 
and excision of the hyperplastic glands was longer, causing less tracer retention, which 
may explain the difference in results.
The probe may produce false-positive findings using the 20% rule in the presence 
of thyroid nodules.70,71 We encountered 2 false-positive findings resulting in a specificity 
of 92%. Inflammatory reactions in 2 small thyroidal nodules causing high Sestamibi 
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uptake may explain these false positive findings. Based on these results with a high 
sensitivity and specificity of the probe in confirming the presence of hyperplastic 
glands after resection, nowadays we perform frozen section analysis only for the 
parathyroid gland that is used for autotransplantation. However, further investigation 
is needed before frozen-section analysis can be obviated. 
The probe also was used in this study for guiding the resection to localize 
parathyroid tumors. In pHPT the probe has shown to be helpful in localizing 26% 
to 66% of the parathyroid glands, particularly in reoperations.71,72 In sHPT the probe 
has been shown to be effective in localizing residual glands during reoperations.73 A 
recent study described successful use of the probe with a sensitivity of 73% in finding 
hyperplastic glands based on in vivo radiation counts in regions around the left and 
right thyroid lobes.74 In contrast we used the judgment of the surgeon in this study 
as a subjective measurement to evaluate the probe’s usefulness in localizing missing 
glands after inspection of the area dorsal of the thyroid. It should be emphasized 
that in our patients with sHPT the intraoperative gammaprobe was found helpful in 
localizing at least 1 parathyroid tumor in 9 of the 29 patients (31%) and in 13% (14 of 
104) of the hyperplastic glands. All other glands were localized easily without the help 
of the probe or diffuse signals were measured with the probe not leading to early 
gland localization. The probe facilitated localization of 40% (4 of 10) of the ectopic 
hyperplastic glands, concerning 4 of the 9 patients in which the probe was helpful. 
The lower rate of localizing ability of the gammaprobe in secondary as compared with 
pHPT can be explained by multiple areas of radioactivity in the neck and around the 
thyroid present in sHPT, whereas the thyroid always provides considerable background 
activity. Concerning guiding the resection in sHPT, the probe seems most helpful in 
localizing ectopic glands.
Many surgeons do not believe that preoperative or intraoperative localization 
studies affect surgical strategy in sHPT because limited surgery is not feasible and 
localization studies show low sensitivity. Some investigators claim high sensitivities 
(77%–91%) with subtraction scintigraphy22,38, but more often low sensitivities (44%–
54%) are reported.17-20 Numbers in this study showed a sensitivity of 41%. In our 
institute sensitivity was 54% over the past decade using dual-phase 99MTc-Sestamibi 
scintigraphy plus single-photon emission computerized tomography and did not 
improve using additional imaging techniques such as 123I-subtraction.
Although preoperative scintigraphy with its low sensitivity seems of little surgical 
value, intraoperative scintigraphy using the gammaprobe can affect surgical strategy. 
This study showed that the gammaprobe is more effective in identifying hyperplastic 
parathyroid tumors using the 20% rule after resection compared with preoperative 
scintigraphy. The probe provides immediate information whether the resected tissue 
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is indeed hyperactive parathyroid tissue instead of waiting for fresh-frozen section 
analysis. Although the localizing ability of the probe was low in general, it was helpful 
in localizing some parathyroid glands that were not identified on preoperative 
scintigraphy, especially ectopic glands. The latter phenomenon has been reported 
before in both primary and secondary disease and frequently the glands had an 
ectopic localization.66,68,73,75,76 Apparently, a probe close to the parathyroid tumor is 
more sensitive than the gamma camera used in the preoperative setting. Moreover, 
the probe can selectively detect radioactivity behind structures such as the thyroid, 
whose radioactivity may interfere during preoperative scintigraphy. Because of the 
limited value of preoperative scintigraphy, we perform radio-guided surgery without 
preoperative scintigraphy in sHPT nowadays.
One of the reasons to explore the usefulness of the probe in sHPT was the relative 
high failure rate of PTx. Reasons for surgical failure are identification of less than 4 usual 
glands, ectopic glands, or supernumerary glands that can be present in up to 30% 
of the patients.10,59,60,77 Routine thymectomy at primary surgery is advocated because 
supernumerary glands usually are situated in the thymus. In our study the probe was 
able to facilitate localization of at least 1 gland in 31% of the patients. However, the 
probe did not prevent that in 22% of the patients undergoing primary surgery less 
than 4 glands were identified, resulting in an 11% surgical failure rate according to 
biochemical follow-up evaluation. The failure rate in the patient population before use 
of the gammaprobe intraoperatively was 13% (data not presented) and not different 
from the current study group. Therefore, the impact of the probe on the success rate 
of parathyroid localization in secondary disease is uncertain.
CONCLUSION
The gammaprobe can be a useful tool in sHPT. It can confirm the presence of 
hyperplastic glands after resection. The usefulness of the gammaprobe in guiding the 
bilateral exploration in sHPT is limited in case of normal localization of the parathyroids, 
although it can be valuable to identify ectopic hyperplastic glands. The gammaprobe 
can localize and affirm resection of hyperactive parathyroids not detected on 
preoperative scintigraphy.
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Introduction: P-glycoprotein (P-gp) and multidrug resistance-associated protein 
(MRP) are membrane efflux pumps that may have a role in the kinetics of 99mTc-
Sestamibi in parathyroid tumors. P-gp and MRP1 expression in parathyroid tumors 
was studied and related to histology, weight and pre- and intraoperative Sestamibi 
imaging results. 
Methods: Thirty-three patients underwent radioguided parathyroidectomy (PTx) for 
primary (pHPT) or secondary hyperparathyroidism (sHPT) in a tertiary referral center. 
Main outcome measures were P-gp and MRP1 expression. Dual-phase 99mTc-Sestamibi 
scintigraphy and SPECT results were compared to the surgical findings. Radioactivity 
and weight of resected parathyroid tumors were measured. Intraoperative radioactivity 
measurements were decay corrected. After routine histology immunohistochemistry 
was performed using C494 monoclonal antibodies to P-gp and MRP1r1 to MRP1. P-gp 
and MRP1 expression were scored covering both distribution of positivity and degree 
of immunostaining semi quantitatively. 
Results: P-gp and MRP1 staining was observed in 97% and 43% of the glands 
respectively. P-gp staining was positive in 91% (21/23) of the adenomas and in all 36 
hyperplastic glands. MRP1 staining was positive in 22% (5/23) of the adenomas and 
in 61% (22/36) of the hyperplastic glands. P-gp or MRP1 expression did not correlate 
with preoperative 99mTc-Sestamibi  imaging or intraoperative radioactivity. Parathyroid 
weight was associated with preoperative Sestamibi imaging results and Sestamibi 
uptake measured during surgery.
Conclusion: P-gp and MRP1 expression did not correlate with 99mTc-Sestamibi  uptake 
in parathyroid tumors. Parathyroid weight remains the major known factor influencing 
99mTc-Sestamibi  uptake.
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INTRODUCTION
In pHPT preoperative localization is important for an appropriate minimal invasive 
surgical procedure.15 99mTc-Sestamibi scintigraphy has a high sensitivity up to 90 % in 
detecting solitary adenomas in pHPT.2 The sensitivity is lower in identifying adenomas 
or hyperplastic glands in multiglandular disease (44–54%).17-19 The mechanisms 
of uptake and elimination of 99mTc-Sestamibi are still unclear and the difference in 
sensitivity is difficult to explain. 99mTc-Sestamibi  is concentrated in both thyroid and 
parathyroid tissues. The dual phase imaging technique is based on a slower washout 
of 99mTc-Sestamibi  in parathyroid tumors compared to adjacent normal thyroid tissues. 
It is suggested that the elimination of 99mTc-Sestamibi is related to the expression of 
transmembrane transport protein, the P-glycoprotein (P-gp) in parathyroid tumors.78-80 
Influx is driven by the combined effect of electronegative plasma membrane and 
mitochondrial membrane potentials countered by the efflux transport of 99mTc-
Sestamibi mediated by P-gp and to a lesser extent by multidrug resistance-associated 
protein (MRP1). P-gp and MRP1 are ATP-dependent efflux pumps that rapidly eliminate 
lipophilic cations such as chemotherapeutic agents and Sestamibi from tumor cells.81 
Some authors described an increase in 99mTc-Sestamibi  uptake by inhibition of P-gp.82,83 
It is hypothesized that parathyroid tumors with low or no expression of P-gp or MRP1 
may have a higher accumulation of 99mTc-Sestamibi . This in turn may lead to an 
improved detection rate of parathyroid tumors by administering selective competitors 
or inhibitors of P-gp or MRP1.78,84 In this study we evaluate the expression of P-gp and 
MRP1 in parathyroid tumors in relation to histology, tumor weight and 99mTc-Sestamibi 
pre- and intraoperative imaging results.
PATIENTS AND METHODS
Patients 
In the period of November 2001 till October 2003 we included 33 consecutive patients 
with biochemical proven hyperparathyroidism who underwent PTx. There were 26 
female and 7 male with a mean age 60 ± 12 years. Twenty patients presented with pHPT 
and 10 patients with sHPT. One patient had a MEN-1 syndrome, one patient developed 
hyperparathyroidism after a period of taking medicine containing phosphate as part 
of treatment for x-linked hypophosphatemic rachitis and one patient had a lithium 
induced hyperparathyroidism. Informed consent was obtained from all patients with 




Dual-phase and SPECT imaging were performed on a Siemens Multispect 2 
gammacamera with a low-energy high-resolution collimator (symmetric 15 % window 
over 140 keV). Ten minutes after intravenous injection of 400 MBq 99mTc-Sestamibi, 
early static images were obtained with an acquisition time of 10 min (128x128 matrix). 
SPECT images were obtained 90 min after injection (180 o , 2x32 views during 30 sec) 
followed by late static images 120 min after injection with an acquisition time of 10 min. 
SPECT images were reconstructed using an iterative reconstruction method. Images 
were visually reviewed by two experienced nuclear medicine physicians aware of 
clinical characteristics but blinded to results of other localization studies. SPECT images 
were observed after the judgments of the early and late planar images. Agreement 
of suspected foci relative to normal thyroid was reached by discussion. A positive 
finding was defined as a focus of increased 99mTc-Sestamibi uptake in the cervical area 
or mediastinum characterized as a relative increase of radioactive intensity from the 
early (thyroid) phase to the late (parathyroid) phase that could not be attributed to 
normal physiologic uptake. The scintigraphic location of lesions was compared with 
the surgically identified location. 
Surgery 
Minimal invasive radioguided PTx was performed in pHPT with a uniglandular lesion. 
Bilateral exploration was carried out in case of negative preoperative localization 
imaging or in multiglandular disease. Patients with sHPT underwent total PTx with 
auto-implantation in the sternocleidomastoid muscle. Patients with MEN-1 syndrome 
or lithium-induced hyperparathyroidism underwent bilateral exploration. One patient 
with hyperparathyroidism after using phosphate medication underwent unilateral 
exploration.
A gammaprobe (Neoprobe 2000; Neoprobe Corp, Dublin, Ohio) was used 
intraoperatively in patients with preoperative positive scintigraphy. These patients 
received an i.v injection of 460 ± 77 MBq 99mTc-Sestamibi  105 ± 35 min before 
incision. After identification and excision of suspected parathyroid tumors the relative 
radioactivity was determined, defined as radioactivity ex vivo in counts per second 
(cps) divided by wound bed radioactivity (cps). The highest level of activity in excised 
tissue was taken as tissue activity. If the relative intraoperative radioactivity of the ex-
vivo tissue was higher than 20% related to the postexcisional background counting 
of the adjacent normal tissue, the removed tumor was considered to be parathyroid 
tissue.13 Histopathological confirmation was obtained by frozen section analysis and 
intraoperative PTH monitoring was performed. Radioactivity measurements of the 
glands after excision were decay corrected to the time of injection and expressed as 
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percentage of injected dose (%ID). Surgery was considered successful if serum PTH 
and calcium were not elevated within six months after surgery. 
Histology and immunohistochemistry 
Histology was obtained after routine fixation. Parathyroid glands were defined 
abnormal when their weight exceeded 55mg.25 Glands were defined as an adenoma 
if hypercellularity was found in ≤2 glands in the presence of one or more normal 
appearing glands or in combination with normalization of parathyroid hormone (PTH) 
and calcium within six months after resection. Glands were defined hyperplastic if 
hypercellularity was seen in 3 excised glands of one patient.65 Weight was measured 
by the pathologist directly after resection. Glands that were used for auto-implantation 
in patients with sHPT could not be weighed. Immunohistochemistry was performed 
as previously described.85 In summary, heat-induced epitope retrieval was performed 
after deparaffinization. Samples were incubated with the primary antibody for one hour 
at room temperature. The following monoclonal antibodies were used: C494 (Signet 
Laboratories, Dedham MA, USA; dilution 1:200) to P-gp; MRP1r1 to MRP1 (dilution 1:100).86 
The staining procedure consisted of an indirect immunoperoxidase method using rabbit 
antimouse (C494) or rabbit anti-rat (MRP1r1) peroxidase conjugated immunoglobulins 
(Dako, Glostrup, Denmark). Bound peroxidase was developed with diaminobenzidine 
and hydrogen peroxidase. Samples were counterstained with haematoxylin. Positive 
controls were tumor tissue samples, found on previous occasions to stain positive for 
P-gp or MRP1. For the negative controls, no antibody was added. Both the expression of 
P-gp and MRP1 was determined on normal and pathological parathyroid tissue samples. 
Scoring of immunoreactivity 
Slices were scored independently by two observers familiar with immunohistochemistry 
without knowledge of the clinical data.85 Consensus was reached after discussion. Only 
membrane bound P-gp and MRP1 staining was considered positive. P-gp and MRP1 
expression were assessed using a semi quantitative scoring system covering both 
the distribution of positive cells and the intensity of immunostaining as advised in 
consensus recommendations.87 Percentages of negative, weak, moderate and strong 
staining in the slice were estimated. Strong staining was defined as comparable to 
the strongest stained slice of all tissue slices. Total score per gland was computed as 
follows: total score = ( % no uptake * 0) + ( % mild staining * 1) + ( % moderate staining 
* 2) + ( % strong staining * 3).85 In concordance with former publications, samples 





Statistical analysis was performed using Student ’s t-test, Mann-Whitney U test, Chi-
square or Fisher exact test, Spearman correlation coefficient or linear regression 
analysis as appropriate (two-sided p-value < 0.05 was considered significant). Data 
are presented as mean ± SD throughout. Calculations were performed using SPSS for 
Windows, version 11.5 (SPSS Inc, Chicago, ILL). 
RESULTS
Preoperative data 
Sensitivity of preoperative 99mTc-Sestamibi  scintigraphy was 78% for adenomas and 
50% for hyperplastic glands. Six out of 23 adenomas were located ectopically (para-
vertebral, thymic or para-esopageal region) and 5 of these 6 were correctly identified. 
Five out of 36 hyperplastic glands were located ectopically (thymic or para-esophageal 
region) and 2 of these 5 were correctly localized. The preoperative serum calcium 
and PTH of patients with pHPT was 2.88±0.20 mmol/l (normal 2.25–2.75 mmol/l) 
and 21±15 pmol/l (normal <10 pmol/l) respectively. In sHPT the preoperative serum 
calcium and PTH of patients was 2.57±0.23 mmol/l and 108±66 pmol/l (normal <20 
pmol/l) respectively.
Surgical outcome 
Surgery for pHPT was successful in 19 out of 20 patients with excision of 17 single 
adenomas and two double adenomas. In one patient surgery failed as no abnormal 
parathyroid gland was identified. A single adenoma and two normal parathyroids were 
removed in the patient with MEN-1 syndrome. In the patient with hyperparathyroidism 
after phosphate medication a single adenoma was found. According to positive 
preoperative scintigraphy, the probe was applied in 18/21(86%) patients presenting 
with adenomas. Identification of resected parathyroid tissues was obtained by 20% 
rule with measurement of radioactive counts in 21/23(91%) adenomas and in 2/4 
normal parathyroids. 
Thirty-two hyperplastic glands were found in 10 patients with sHPT and 4 
hyperplastic glands in the patient with lithium induced hyperparathyroidism. Surgery 
was successful in all these patients according to biochemical follow-up, but in one 
patient with a bilateral re-exploration only normal parathyroid tissue was found in the 
sternocleidomastoid muscle at the implanted site of prior surgery. According to positive 
preoperative scintigraphy, the probe was applied in 10 of the 11 patients presenting 
with hyperplastic glands and radioactive counts were obtained of 32/36(89%) of the 
resected hyperplastic glands. 
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Figure 1: Positive P-gp staining. A) Strong positive staining of P-gp on the membrane of 
parathyroid cells. B) Positive MRP1 staining that demonstrates the variability in degree of staining.
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P-gp and MRP1 expression related to histology 
Positive immunostaining for P-gp was observed in 21/23 (91%) adenomas and 
in 36/36 (100%) of the hyperplastic glands (figure 1). Total staining scores covering 
both distribution and intensity of P-gp staining, were not different for adenomas 
and hyperplastic glands (figure 2). Varying P-gp intensity scores within the same 
parathyroid tumor were observed in 11/23 (48%) adenomas and in 26/36 (72%) 
hyperplastic glands (p=0.059). These tumors consisted mainly of several nodules that 
were mutually divergent in P-gp staining intensity. Normal parathyroid glands showed 
positive P-gp staining. Thyroid tissue stained negative for P-gp.
Figure 2: Immunostaining scores 
for P-gp and MRP in adenomas, 
hyperplastic and normal parathyroid 
glands.
Positive staining for MRP1 
was observed in 5/23 (22%) 
adenomas and in 22/36 (61%) 
hyperplastic glands (p=0.003). 
Immunostaining scores for MRP1 
were significantly higher in 
hyperplastic glands as compared 
to adenomas (75 ± 86, median 40 
vs. 27 ± 65, median 0 respectively, 
p=0.025; figure 2). Heterogeneity 
in the degree of immunostaining 
within tumors was observed 
in 3/23 (13%) of the adenomas 
compared to 22/36 (61%) of the 
hyperplastic glands (p<0.001; 
figure 1b). Mostly these different 
degrees of immunostaining coincided with the different nodules within the tumor. 
Normal parathyroid tissue and thyroid tissue showed negative MRP1 staining. Besides 
heterogeneity in immunostaining for P-gp and MRP1 within parathyroid tumors, there 
was heterogeneity between different parathyroid tumors within the same patient, 
especially for MRP1 immunostaining. Considering only the patients with pHPT and 
sHPT similar results were obtained as described for adenomas and hyperplastic glands 
respectively. 
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Figure 3: Immunostainingscores for P-gp 
(A) and MRP (B) according to preoperative 
99mTc-Sestamibi  scintigraphy results. TP = 
true positive ; FN = false negative ; n = 
number.
P-gp and MRP1 expression related 
to 99mTc-Sestamibi imaging results 
Glands with true positive and false 
negative preoperative scintigraphy 
results showed no differences in 
positive P-gp staining (94% vs.100%) 
or total P-gp staining score (211 ± 
84 vs. 189 ± 67) (figure 3a). There 
was no relationship between the 
intraoperatively measured radioactivity 
(% ID) per gland and the P-gp staining 
score, even not when corrected for 
tumor weight. No differences could 
be demonstrated either by analyzing 
adenomas and hyperplastic glands 
separately. 
MRP1 staining was equally positive 
in 11/23 (48%) glands not identified on 
preoperative scintigraphy compared to 
16/36 (44%) glands that were identified. Total MRP1 score was not different for both 
groups (figure 3b). There was no relation between MRP1 score and intraoperatively 
measured radioactivity (% ID), neither when corrected for weight or separately analyzed 
for adenomas and hyperplastic glands. Glands with both MRP1 and  P-gp scores below 
the mean were not associated with positive preoperative scintigraphy results.
Weight related to 99mTc-Sestamibi imaging results 
Weights of true-positive glands differed significantly from false-negative glands (1444 
± 1026 mg vs. 601 ± 587 mg, p=0.003). Parathyroid weights correlated positively with 
the measured radioactivity during surgery (% ID) (r=0.45, p=0.002). Mean weight of 
adenomas was not significantly different from hyperplastic glands; 1394 ± 1233 mg 
compared to 957 ± 661mg, respectively. No association was observed between weight 
and intraoperatively measured radioactivity (% ID) for adenomas (R2=0.015, p=0.591), 
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though there was a significant relation between weight and intraoperatively measured 
radioactivity for hyperplastic glands (R2=0.59, p<0.001). Gland weight showed to be an 
important factor for Sestamibi uptake and retention in hyperplastic glands, but was 
less important in adenomas. 
DISCUSSION
Since the introduction of parathyroid imaging with 99mTc-Sestamibi  in 1989, factors 
that may determine uptake and retention of 99mTc-Sestamibi are subject of debate.89 
Sestamibi, a lipophilic cationic complex, is bound to positively charged Technetium. 
99mTc-Sestamibi  crosses membranes by diffusion and passive transmembrane 
distribution. One of the known mechanisms is the influence of size and blood flow on 
the uptake activity of 99mTc-Sestamibi . 90  However, this metabolic hyperactive model 
fails to explain why occasionally large parathyroid tumors are not visualized whereas 
small tumors are strongly visualized.91,92 Another theory is that the degree of Sestamibi-
uptake may correlate with parathyroid proliferation and different phases of cell cycles 
(G2 / S growth phase) of the glands, which seems to be higher in nodular hyperplastic 
glands compared to the diffusely hyperplastic glands.47 And it has been suggested 
that 99mTc-Sestamibi  uptake is related to the percentage of oxyphil cell content in 
parathyroid tumors, the mitochondrial model, and biochemical levels, however with 
conflicting results that do not give a satisfying explanation for differences in 99mTc-
Sestamibi  retention.91,93 
Lately retention of 99mTc-Sestamibi  has been related to the expression of P-gp 
and MRP1 in parathyroid tumors. Axiotis et al first demonstrated P-gp expression in 
parathyroid glands and observed weaker immunoreactivity for P-gp in adenomas 
as compared to hyperplastic glands that are known for their low sensitivity in 99mTc-
Sestamibi  scintigraphy.94 Several authors have suggested an inverted relationship 
between P-gp expression as measured by immunostaining and parathyroid tumor 
detection by 99mTc-Sestamibi  scintigraphy.79,88,95-97 Recently, Gupta et al. found a 
discordance of 33 % in the proportion of P-gp membrane staining and the Sestamibi 
scan results.98 Some authors showed similar results using Tetrofosmin instead of 
Sestamibi.45,78,84 Tetrofosmin is comparable to Sestamibi for parathyroid tumor 
detection and is also a ligand for P-gp and MRP1. 
In contrast to the previous studies, we found no relationship between the 
expression of P-gp on parathyroid cell membranes and the detectability of parathyroid 
tumors with 99mTc-Sestamibi  scintigraphy. Even adenomas with a clear hotspot on 
preoperative scintigraphy and high intraoperative radioactive measurements 
showed a strong overall P-gp immunoreactivity. Others, Bhatnagar et al and Turgut 
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et al did not find a relation between the level of P-gp expression and 99mTc-Sestamibi 
scintigraphy.99,100 Ugur et al described a highly variable expression of P-gp in pHPT 
like shown in this study.101 P-gp expression did not correlate with preoperative 99mTc-
Sestamibi  scintigraphy results. In contrary they found a weak inverse correlation 
between intraoperative measured radioactivity and P-gp expression in adenomas of 
patients with pHPT, but not in hyperplastic glands of patients with tHPT.101 Similar to 
Yamaguchi et al.96, we found high positive P-gp immunoreactivity in both adenomas 
and hyperplastic glands, whereas others describe predominantly negative staining in 
adenomas 45,78,84,88,95 and positive staining in 0 – 46 % of the hyperplastic glands.95,96 
MRP1 expression studies in parathyroids also show varying results. Yamaguchi et al 
reported no relation between MRP1 expression and scintigraphy results in either 
adenomas or hyperplastic glands as opposed to Shiau et al, who suggested that 
MRP1 expression influenced 99mTc-Tetrofosmin imaging.84,96 In this study no evidence 
was found for a relationship between P-gp or MRP1 expression and 99mTc-Sestamibi 
imaging results, although it might play a role in individual patients. 
Considerable differences in results of the P-gp and MRP1 transmembrane efflux 
pump mechanism between studies might be due to differences in the applied antigen 
retrieval method, the type of antibodies used and the method of immunostaining and 
scoring of reactivity. Although P-gp is known as an integral membrane glycoprotein, 
cytoplasmic immunostaining seems to be considered as positive staining in several 
studies.45,78,84,88 NCL-JSB-1 (Novacastra laboratories, New Castle upon Tyne, UK) is used 
as an antibody in a number of these studies. Cytoplasmic JSB-1 staining has been 
suggested to reflect an artifact by Faneyte et al. because it did not correlate with MDR1 
/ P-gp mRNA level.102 
In most studies a qualitative or semiquantative score of scintigraphic imaging 
results is used to determine the relation between 99mTc-Sestamibi  uptake and 
expression of P-gp or MRP1. We used both a qualitative score of preoperative imaging 
results and a direct quantitative measure of 99mTc-Sestamibi  uptake obtained during 
surgery with the gammaprobe. Although the gammaprobe equipped with a collimator 
cannot measure radioactivity of glands as precise as a gammacounter, it seems to 
estimate 99mTc-Sestamibi  retention in glands better than qualitative or semiquantative 
measurements of preoperative scintigraphic images. 
Most studies report a relation between size and detectability with 99mTc-Sestamibi 
scintigraphy of parathyroid tumors.91,92,96 Size alone is not a guarantee for Sestamibi 
uptake, but as large-sized parathyroid tumors are frequently accompanied by an 
increased blood flow, both factors may lead to a higher rate of positive scans in 
these tumors. Factors that also have been related to 99mTc-Sestamibi  uptake are the 
percentage of oxyphil cell content in parathyroid tumors and biochemical serum 
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levels. Uptake of lipophilic cations like Sestamibi is high in tissues with negative plasma 
membrane potentials and with relatively high mitochondrial content. At least 92 % of 
the Sestamibi retention has been found in the mitochondria of parathyroid tumors.91 
Parathyroid tumors contain mainly chief cells and oxyphil cells of which the latter are 
rich in mitochondria. Some morphologic studies have related a high percentage of 
oxyphil cell type to 99mTc-Sestamibi  uptake in parathyroid tumors 93, however this 
could not be confirmed by others.91,99,100 Mostly preoperative serum PTH has been 
associated with a higher degree of 99mTc-Sestamibi  uptake.91,92 A few studies related 
serum calcium levels to 99mTc-Sestamibi  uptake, that might be explained by their effect 
on membrane potentials.91,103 This study confirms the association between weight and 
detection of parathyroid tumors, especially in hyperplastic glands. The fact that nor 
weight or the presence of P-gp or MRP1 contributed significantly to 99mTc-Sestamibi 
retention in adenomas in this study, implicates that other known factors or unknown 
factors played a role in the mechanism of uptake and retention in these adenomas. 
Whether polymorphism of the multidrug-resistance gene (MDR)-1 gene encoding 
P-gp may affect the functionality of P-gp in the retention of 99mTc-Sestamibi  in 
parathyroid tumors remains questionable and should be further examined.104 However, 
so far we think there is insufficient evidence to explore the use of selective inhibitors of 
P-gp or MRP1 in the future in order to enhance 99mTc-Sestamibi  scintigraphy. 
CONCLUSION
We observed varying expression of P-gp and MRP1 within parathyroid tumors, within 
patients and between patients. However, we did not observe any relation between 
the 99mTc-Sestamibi  imaging results in parathyroid tumors and the presence of P-gp 
or MRP1 on the membrane of parathyroid glands. Weight remains the major factor 
influencing 99mTc-Sestamibi  imaging results, especially in hyperplastic glands, although 
other known or unknown factors may play a role in individual cases.  
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Introduction: Aim of this study was to analyze our results of intraoperative parathyroid 
hormone (ioPTH) monitoring during parathyroidectomy (PTx) in secondary (sHPT) and 
tertiary hyperparathyroidism (tHPT) and evaluate its clinical utility in these patients.
Methods: Retrospective analysis of 50 patients with sHPT or tHPT undergoing total 
PTx with or without auto-implantation. ioPTH samples were acquired after induction 
of anesthesia, at the moment of resection of the last enlarged parathyroid gland and 
5, 10 and 15 min hereafter. 
Results: A decrease >50% 10 minutes after successful total PTx was seen in 98% of 
the patients. A decrease >80% at 10 and 15 minutes was seen in 89% and 91% of 
the patients respectively. Using 50% cut-off level at 10 minutes sensitivity was 100%, 
specificity 17%, positive predictive value (PPV) 100%. Using 80% cut-off level at 10 
minutes sensitivity was 91%, specificity 83%, PPV 98%, negative predictive value (NPV) 
56%. Using 80% cut-off level at 15 minutes sensitivity was 93%, specificity 67%, PPV 
98%, NPV 57%. False positive and negative results are worked out.
Conclusion: ioPTH monitoring has high PPV but low NPV. Considering  the multiple 
factors influencing ioPTH in sHPT and the high pre-test probability for surgical cure 
after resection of four parathyroid glands, we do not recommend standard use of 





Intraoperative PTH monitoring has developed to a standard of care procedure 
during PTx for primary pHPT. It predicts surgical cure if the PTH level shows ≥50% 
decrease after resection of an adenoma within 5-10 minutes with a sensitivity of 98% 
and a specificity of 91%.105 A minimal invasive PTx based on adequate preoperative 
localization, combined with ioPTH monitoring has proved to be effective in reducing 
the possibility of overlooking multiple gland disease, while minimizing operative time, 
and  potential morbidity. 
Intraoperative PTH monitoring in case of sHPT is different for several reasons. First 
ioPTH monitoring is complex in these patients because of impaired renal function and 
delayed clearance of PTH. Secondly, a bilateral exploration has to be performed in all 
cases with (sub)total excision of all parathyroid glands.  
In comparison with surgery for pHPT, the rate of persistent or recurrent disease is 
high in sHPT, ranging from 3%- 12%.106,107 Therefore ioPTH monitoring is thought to 
be helpful in predicting adequate resection of hyperactive parathyroid tissue. Several 
authors report that ioPTH monitoring is an useful tool by identifying patients with 
supernumerary parathyroid glands or minimizing surgical exploration in patients with 
fewer than four parathyroid glands and preventing blind thymectomies.108-110,110-119 
However others have concluded that PTH cannot adequately predict the resection of 
all hyperactive parathyroid glands.117,120-124 Therefore the utility of ioPTH monitoring in 
sHPT remains uncertain. 
Intraoperative PTH monitoring was introduced in our institution in 2002 and is the 
current standard of care for all parathyroidectomies. Aim of this study was to analyze 
our results of ioPTH monitoring during PTx in sHPT and tHPT in our institution and to 
evaluate its clinical utility in these patients.
METHODS
Patients
Intraoperative PTH analysis was introduced in our tertiary referral hospital in January 
2002. The medical records of all patients who underwent PTx for sHPT or tHPT at 
our institution between January 2002 and December 2010 were reviewed. Clinical 
characteristics, surgical findings and results of ioPTH monitoring and pre- and 




Preoperative parathyroid imaging was variable during the study period, including 
ultrasonography, 99MTc-Sestamibi scintigraphy, and computed tomography. In 
case of sHPT and tHPT total PTx was performed with auto-implantation of a partial 
parathyroid in the sternocleidomastoid muscle. Intraoperative gammaprobe was 
used for confirmation of hyperactive parathyroid tissue after resection as described 
previously by Jorna et al.125 Standard exploration was focused on the usual anatomic 
sites. Thymectomy was not performed routinely. However, if fewer than 4 glands 
were identified, then was the gammaprobe used for guidance and, if necessary, the 
exploration was proceeded with systematic sequential ipsilateral dissection of the 
thymus, exploration of level VI, the retropharyngeal space, retroesophageal space and 
the carotid sheath. In case of pHPT minimal invasive radioguided PTx was performed 
if feasible.125 
Surgery and pathology reports of all patients were reviewed. Parathyroid glands 
were defined as abnormal if they weighed more than 55 mg or their largest diameter 
exceeded 7 mm at surgical or pathologic examination.25 Glands were defined as an 
adenoma if hypercellularity was documented in 2 or fewer glands in the presence of 1 or 
more normal-appearing glands. Glands were defined as hyperplastic if hypercellularity 
was documented in 3 or more excised glands 65. 
Intraoperative PTH monitoring 
In case of sHPT or tHPT a baseline ioPTH level was drawn prior to skin incision but after 
the introduction of anesthesia. After bilateral exploration further samples were drawn 
at the moment of excision of the last (in most cases the fourth) parathyroid gland and 
5, 10 and 15 min hereafter. Results of ioPTH values were reported to the surgeon intra- 
or postoperatively, but had no clinical implication. 
Baseline was defined as the higher of the two pre-excision values. Two different cut-
off levels (50% or 80% decrease after 10 and 15 minutes) were applied. These values 
were chosen as 50% is an often used cut-off value in both pHPT and sHPT/tHPT114,123,126, 
whereas 80% is a more stringent value used by others.115 A true positive result is 
defined as a decrease in ioPTH >50% or >80% at 10 and 15 minutes from baseline and 
no signs of persistent disease during follow-up. A false positive results is defined as a 
sufficient decrease with persistent disease during follow-up or sufficient decrease after 
resection of less than four glands while afterwards intraoperative another enlarged 
gland was identified. A true negative result is defined as an insufficient decrease with 
intraoperative evidence of an enlarged gland left in situ or persistent disease during 
follow-up. A false negative result is defined as an insufficient decrease without signs of 
persistent disease during follow-up.
Intraoperative PTH monitoring
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PTH analysis and intraoperative PTH monitoring was performed with the ILMA 
advantage (Nichols) intact PTH assay from January 2002 till February 2006 and 
thereafter with the Immulite 2500 intact PTH assay (Siemens). The relative amount 
of decrease from baseline is influenced by the change of method and is presented 
as percentage of baseline value. However to present actual serum PTH levels the 
following conversion factor was applied: Immulite (pmol/l) =[Advantage (pmol/l) + 
0,5] / 0.79 (based on comparison of both assays and Passing Bablok regression analysis 
(EP9-CLSI protocol using EP evaluator).
Persistent / recurrent disease 
Persistent disease caused by unsuccessful surgery for sHPT or tHPT was defined 
as serum calcium > 2.75 mmol/l in combination with a PTH > 20 pmol/l within six 
months after surgery or the need for lowering calcium in the dialysate in combination 
with a PTH > 20 pmol/l. Any increase in PTH and calcium or phosphate refractory to 
treatment after this 6-month period was considered recurrent disease. 
RESULTS
Surgical results
There were 50 patients with sHPT or tHPT, 23 men and 27 women. The age at PTx 
was 49±15 years. In total 39 patients underwent surgery for sHPT 61±43 (range 13-
115) months after starting hemodialysis, 4 patients underwent surgery before starting 
hemodialysis and 7 patients underwent surgery for tHPT 4-107 months after successful 
renal transplantation. 
PTx was successful in 47 (47/50; 94%) patients according to the given definition with 
a follow-up of at least six months. All patients underwent a bilateral exploration. Primary 
surgery was performed in 48 patients: 46 patients had total PTx with auto-implantation 
and two patients total PTx. Two patients, who had their primary surgery elsewhere, 
underwent a reoperation for residual disease. In seven patients the gammaprobe 
could not be used because of logistic problems. One patient was reoperated for 
hemorrhage and one patient had transient recurrent nerve paralysis postoperative. 
Twenty-four patients showed postoperative hypocalcaemia necessitating extra 
calcium medication for more than 2 weeks. Pre- and postoperative serum calcium and 
PTH levels are shown in table 1. 
During primary surgery four hyperplastic glands were identified in 34 of the 48 
patients. Five hyperplastic glands were resected in four and six hyperplastic glands in 
two of these 48 patients.
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Table 1: Pre- and postoperative serum calcium and PTH levels
PTH (pmol/l) Calcium (mmol/l)*
Preoperative 141±85 2.54±0.29
day 1 4.8±8.1 2.12±0.25
6 months 7.7±8.7 2.28±0.28
* Serum calcium was corrected for serum albumin.129
In 7 of the 48 patients only three hyperplastic glands were identified of whom 3 showed 
persistent HPT postoperative. In one patient only one normal parathyroid was identified 
and resected during primary surgery. Despite these negative operative findings in this 
latter patient, PTH decreased from 74 pmol/l to 5,6 pmol/l and sustained below 20 
(pmol/l) during the first year after surgery. During two reoperations for residual disease 
two residual glands and the reimplanted tissue were resected. Mean weight of all 
these hyperplastic glands was 852±743mg. The patient was in the operating room 
(including time for surgery and anesthesia both pre- and postoperatively) during an 
average of 201±65 minutes. 
Results intraoperative PTH monitoring 
In total 98% of the patients with sHPT or tHPT undergoing a successful primary PTx 
showed a decrease >50% as compared to baseline both 10 min and 15 minutes after 
resection of the last parathyroid gland. In total 89% of the patients showed a decrease 
>80% at 10 min and 91% of the patients a decrease >80% at 15 minutes. Figure 1 
shows the PTH as compared to baseline at the different time points. There was no 
difference in the relative decrease of ioPTH between patients with sHPT and tHPT. 
Results of sensitivity and specificity while using different cut-off levels at different 
times are shown in table 2. The intraoperative PTH results of patients with false positive 
or false negative results are shown in table 3. We observed persistent disease in three 
of the seven patients with resection of 3 hyperplastic glands despite a decrease in 
ioPTH of 76-90% at 15 minutes post total PTx.  In addition we observed false positive 
decreases in two patients after resections of 2 or 3 enlarged glands, while during 
extended exploration in the same session residual enlarged glands were identified and 
resected. Sensitivity and specificity in this select patient group are showed in table 4.
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Figure 1: Intraoperative PTH results in patients with secondary (sHPT) or tertiary 
hyperparathyroidism (tHPT) undergoing successful parathyroidectomy (PTx) (n=45). T=0: time 
at excision of last hyperplastic gland; T=5/10/15 min: number of minutes after excision of last 
hyperplastic gland.
Table 2: Evaluation of sensitivity and specificity in secondary and tertiary hyperparathyroidism 
undergoing primary parathyroidectomy (n=48). 
Decrease from baseline Sensitivity Specificity PPV NPV
>50% at 10 min 100% (44/44) 17% (1/6) 90% (44/49) 100% (1/1)*
>50% at 15 min 100% (44/44) 17% (1/6) 90% (44/49) 100% (1/1)*
>80% at 10 min 91% (40/44) 83% (5/6) 98% (40/41) 56% (5/9)
>80% at 15 min 93% (41/44) 67% (4/6) 95% (41/7) 57% (4/7)
PPV = positive predictive value; NPV = negative predictive value; * numbers are based on one true negative 











































































































































































































































































































































































































































































































































































































































































































































































































Table 4: Evaluation of sensitivity and specificity of ioPTH results obtained after resection of ≤3 
parathyroid glands during primary parathyroidectomy.
Decrease from baseline Sensitivity Specificity PPV NPV
>50% at 10 min (n=8) 100% (4/4) -* 50% (4/8) -*
>50% at 15 min (n=9) 100% (4/4) -* 44% (4/9) -*
>80% at 10 min (n=8) 75% (3/4) 75% (3/4) 75% (3/4) 75% (3/4)
>80% at 15 min (n=9) 75% (3/4) 60% (3/5) 60% (3/5) 75% (3/4)
In one patient adequate samples were only available at 15 minutes. PPV = positive predictive value; NPV = 
negative predictive value; * Numbers could not be calculated because of lack of true negative results in this 
select patient group.
DISCUSSION
Ever since the introduction of ioPTH monitoring during surgery for pHPT by Irvin et al. 14 
in the early 1990’s, it has been performed in patients with sHPT. In published studies 
different surgical strategies, different timing of PTH sampling, different definitions of 
baseline values and different cut-off values and outcome measures have been used. 
Most studies claim that ioPTH monitoring improves surgical results.108-110,110-119 However 
some studies conclude that ioPTH monitoring cannot adequately predict surgical 
success of PTx in sHPT or tHPT.120-124,127  Therefore clinical utility of ioPTH monitoring in 
sHPT and tHPT remains uncertain.  
Intraoperative PTH monitoring in sHPT differs in various aspects with pHPT and is 
influenced by many factors.  Decay kinetics of PTH are different in sHPT. PTH consists 
of a polypeptide chain of 84 amino acids. It is eliminated mostly via the liver, but also 
in part via the kidneys and it is stored in the bones. The N-terminal fragment of PTH 
contains the region that mediates bioactivity and has a half life of 3-4 minutes. The 
C-terminal fragments of PTH (PTH 7-84) are solely eliminated by the kidneys and have 
a longer half-life of several hours.119 Many commercial intact parathyroid hormone 
assays cross-react with non-(1-84)PTH like (7-84)PTH.  In healthy individuals, non-
(1-84) PTH accounts for up to 20% of circulating intact PTH immunoreactivity. In 
hemodialyzed patients, the non-(1-84) PTH may account for up to 55% of intact PTH 
immunoreactivity.128 
Yamashita et al compared a standard assay known as intact PTH that detects 7-84 
PTH fragments, with a new whole PTH assay claimed to measure exclusively 1-84 
PTH.120 In both pHPT and sHPT the  whole PTH assay showed a faster decline. Also the 
decline was similar for pHPT and sHPT in  contrary to the standard used intact PTH 
assay. Freriks et al re-analyzed their ioPTH samples with the whole PTH assay, however, 
without significant improvement of sensitivity and specificity of ioPTH monitoring as 
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compared to intact PTH.118 Like reported by others109,112,114,119, there seems to be limited 
interference of slow decay of PTH fragments measured with the intact PTH assay 
considering the low PTH values post total PTx in our population .109,112,114,119 Whole PTH 
assay is assumed to be more accurate than intact PTH assay, but unfortunately this 
whole PTH immunoradiometric assay is not suitable for intraoperative use. 
The surgical approach in sHPT is another reason for the difficult interpretation of 
intraoperative PTH results in sHPT. Serum PTH samples in sHPT are taken after (sub)
total PTx, resulting in a decrease >50% of ioPTH at the time of resection of the last 
gland in most patients (T=0, figure 1). However Elizondo et al showed at the same time 
point a decrease > 50% in only 4 out of 25 patients.109 Perhaps these differences can be 
explained by shorter operation times by Elizondo et al (79±25 minutes in the operating 
room). Another explanation can be a difference in assay or a difference in order plus 
timing of resection of the glands. Mostly three hyperplastic glands have been already 
excised in a various amount of time, as a result the expected value at the moment 
of excision of the fourth gland is already low.  A few studies describe explicitly they 
visualize first all glands before resection and then choose the largest to be resected 
as last gland before they start sampling.111,118,120 Other factors influencing ioPTH during 
the bilateral exploration in sHPT, is the potential devascularization or stimulation by 
manual manipulation of unresected glands during bilateral exploration.108  We have 
described one patient with sHPT with clinical cure after extensive bilateral neck 
exploration without resection of any hyperplastic parathyroid tissue. 
In our population high sensitivity of 100% was accomplished with a cut-off value of 
>50% decrease in ioPTH 10 minutes after total PTx, however at the cost of false positive 
results with a positive predictive value of 90%. This would mean that one in ten patients 
might present with persistent disease despite sufficient ioPTH decrease. A stringent 
cut-off value of >80% decrease after 10 minutes maintained a sensitivity of 91%, and 
increased specificity up to 83%. However negative predictive value decreased, which 
would translate in unnecessary extended exploration and thymectomy with inherent 
risks and operation time in approximately four out of ten patients. 
Similar high sensitivities of 94-97% and high PPV of 93-100% have been observed 
by others using a cut-off level of 50% decrease at 10 or 15 minutes.111,114,118 Freriks 
et al recommend a decrease > 70% from baseline (pre-incision and post induction 
of anesthesia) at 10 minutes based on receiver operating characteristic curves. Also 
decreases >60% at 10 minutes 108,112, >80% at 20 min 108 or > 90% at 15 min or drop of 
PTH into the normal range 117 have been mentioned to predict surgical success. Conzo 
et evaluated ioPTH monitoring in 35 patients with sHPT using a cut-off  level of >80% 
decrease at 20 minutes after total PTx compared to baseline value (before induction of 
anesthesia). They observed in 6/27 patients with >80% decrease persistent disease. On 




Although we observed high sensitivities and PPV with ioPTH monitoring in 
sHPT, we question its clinical utility. One of the factors determining clinical utility 
of a diagnostic test is the pre-test probability of a disease. In case of sHPT the pre-
test probability of successful PTx after resection of four parathyroid glands is high. 
The surgical success rate of PTx in sHPT is 88-97%. However when ≤3 glands were 
resected, failure rates were between 34% and 72%, which matches our finding of 
43% (3/7 patients).10,59 Considering the high pre-test probability of surgical cure 
after resection of four parathyroid glands in sHPT, the potential benefit of ioPTH 
seems low.  Intraoperative PTH monitoring may be particularly of added value in 
identifying patients with unrecognized supernumerary glands. However, reviewing 
the literature only one patient with sHPT is reported with a true negative result with 
ioPTH monitoring after resection of four glands, in who eventually a large mediastinal 
fifth gland was resected.111 Some authors have advocated ioPTH monitoring to judge 
whether extended exploration can be abandoned after resection of <4 hyperplastic 
glands.108,115 We think that ioPTH monitoring is not suited for this purpose, considering 
the low PPV we observed after resection of ≤3 glands (table 3). It is important to pursuit 
and confirm the resection of at least 4 hyperplastic glands by frozen section analysis, 
extensive surgical experience or the gammaprobe. Caution is warranted using the 
gammaprobe in the presence of nodular thyroid, considering 2 false positive results of 
the intraoperative gammaprobe in patients with persistent disease after PTx (table 3).
In case of tHPT the expected utility of  ioPTH is higher, because up to one third of 
the patients may have a single or double adenoma only.6,48 However in our population 
all 7 patients with tHPT showed four gland hyperplasia and similar decrease of ioPTH 
as compared to sHPT. Both Haustein et al and Pitt et al described successful limited 
PTx of one or two visually enlarged glands with an adequate decrease >50% 10 min 
after resection with a change in surgical management in 16% and 25% of the patients 
respectively.110,114 Cheung et al studied 14 patients with tHPT. Three out of 14 patients 
showed persistent disease despite >80% decrease in ioPTH at 15 min after resection 
of 1, 3 or 4 enlarged parathyroid glands.122 Another patient group that presents with 
involvement of only one or two glands are patients undergoing a reoperation. In our 
population ioPTH monitoring showed true negative  results indicating the presence 
of a second parathyroid remnant  (case 4, table 3).  Considering these results, further 





In conclusion this study shows that ioPTH monitoring has a high sensitivity and PPV 
in patients with sHPT or tHPT, but a low negative predictive value. Considering  the 
multiple factors influencing ioPTH in sHPT and the high pre-test probability of ioPTH 
monitoring for surgical cure after resection of four parathyroid glands, we do not 
recommend standard use of ioPTH monitoring in sHPT. However its possible clinical 
utility in tHPT and reoperations must be further studied. 
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Secondary hyperparathyroidism (sHPT) can complicate renal replacement therapy 
(RRT) in patients with end-stage renal disease. Current medical therapies often result in 
hypercalcemia  and fail to correct hyperparathyroidism, but might be more effective at 
an early stage of disease. The aim of this study was to identify prognostic factors at the 
start and during the first year of RRT for refractory sHPT needing parathyroidectomy 
(PTx) during long-term follow-up. 
Methods: A total of 202 consecutive patients starting RRT between August 1988 and 
August 1996 at our centre with at least 1 year of follow-up were included. Biochemical 
and treatment data at the start and during the first year of RRT were collected. Univariate 
and multivariate analyses were used to identify risk factors for PTx during follow-up. 
Results: Thirty-three patients (16%) needed PTx after 52±23 months of RRT. Need 
for PTx was not different between patients undergoing hemodialysis and peritoneal 
dialysis, but was associated with parameters reflecting calcium and phosphate control 
at start and after 1 year of RRT. In a Cox multivariate model, serum parathyroid hormone 
[relative risk (RR): 1.02 per pmol/l; P<0.001], phosphate (RR: 1.107 per 0.1 mmol/l; P = 
0.002) and alkaline phosphatase (RR: 1.004 per U/l; P = 0.049) after 1 year of RRT were 
independently associated with increased risk for PTx. 
Conclusion: Failure of control of calcium–phosphate metabolism at the start of and 
early during RRT is strongly associated with PTx during long-term follow-up. Given 
the high prevalence of insufficient phosphate control, patients may benefit from 
aggressive correction of serum phosphate in the pre-dialysis and early dialysis period. 
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INTRODUCTION
Secondary HPT develops in chronic renal insufficiency as a consequence of disturbances 
in calcium, phosphate and vitamin D metabolism. It causes renal osteodystrophy and 
soft tissue calcification and contributes significantly to the cardiovascular morbidity 
and mortality in patients with end-stage renal disease (ESRD).130 Despite improvements 
in medical treatment and dialysis therapy, the PTx rate is 3 per 1000 patient-years in 
patients who received renal replacement therapy (RRT) for <5 years and 12–30 per 
1000 patient-years in patients who are treated for 5–10 or >10 years, respectively.62 This 
rate has not significantly improved over the years.62,131 
As parathyroid hyperplasia and associated metabolic disturbances are not easily 
reversed, management is focused at preventing the development and progression 
of sHPT. Treatment with dietary measures, phosphate binding and active vitamin D 
should start in the pre-dialysis period.132 Patients with established sHPT during RRT 
need intensified treatment using intravenous vitamin D. However, these therapeutic 
interventions are not always successful and their full potential is often attenuated by 
the development of treatment-related hypercalcemia  133. New therapies have been 
developed to overcome the latter problem, but their role in treatment and prevention 
of renal hyperparathyroidism is not clear yet.130,133
More aggressive treatment at an early stage of RRT, when the tendency for 
hypercalcemia  is potentially less and hyperparathyroidism is not yet severe, might be 
helpful and more effective in the long run. In order for such an early and aggressive 
approach to be effective, early identification of high-risk patients is a prerequisite. The 
aim of our retrospective single centre study was to identify predictors at the start and 
during the first year of dialysis for the development of severe sHPT for which surgery is 
needed during long-term follow-up. 
METHODS
Patients
Consecutive patients were included in the study if the following criteria were met: first 
dialysis ever was performed at our institution between August 1988 and August 1996 
and duration of RRT at our institution was >1 year. Exclusion criteria were previous renal 
transplantation, PTx before the start or during the first year of RRT and age <18 years. 
Treatment
Hemodialysis (HD) treatment was performed three times weekly with, in most patients, 
cellulose triacetate-based dialysers and single-pass volume-controlled dialysis 
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monitors. Dialysis duration was 3–5 h with a blood flow of 250–350 ml/min and adapted 
to maintain an equilibrated Kt/V >3.0 per week, including residual renal function 134. 
Bicarbonate-based dialysate was used with a standard calcium concentration of 1.50 
mmol/l. Continuous ambulatory peritoneal dialysis (PD) was done by four to five daily 
exchanges with 2000–3000 ml volume. A weekly Kt/V of >1.8 (including residual renal 
function) was aimed for. Standard PD solution contained 1.75 mmol/l calcium. 
Calcium carbonate or calcium-acetate tablets taken with each meal were used as 
oral phosphate binders. A trained dietician adjusted the dose of phosphate binders 
to the estimated phosphate content of that meal. Dose adjustments were made to 
maintain pre-dialysis serum phosphate <2.0 mmol/l. If, due to hypercalcemia , adequate 
serum phosphate levels could not be obtained, the calcium-based phosphate binders 
were partially replaced by aluminum hydroxide under frequent control of serum 
aluminum. Once adequate control of serum phosphate was obtained, all patients 
received oral daily alfacalcidol (0.25 µg once daily) or dihydrotachysterol (0.2 mg once 
daily). If serum calcium was <2.5 mmol/l or if serum parathyroid hormone (PTH) was 
>20 pmol/l or radiographic signs of hyperparathyroidism were present, vitamin D dose 
was increased. If hypercalcemia  was encountered or control of PTH was insufficient, 
vitamin D therapy was switched to intravenous pulse therapy starting at 0.5 µg 
alfacalcidol three times weekly and, if necessary and possible, increased to 2–3 µg three 
times weekly (in use since 1991 at our institution). In case of persistent hypercalcemia 
, dialysate concentrations were lowered to 1.25 mmol/l in HD and 1.00 mmol/l in PD. 
Sevelamer is in use at our institution since 2001, as combination therapy with calcium 
and vitamin D. 
Indications for parathyroidectomy
PTx was considered necessary if, despite optimal medical and dietary treatment, a 
high serum PTH (110±50 pmol/l; range: 36–264 pmol/l) persisted in combination with 
either (i) radiological evidence of renal osteodystrophy; (ii) persistent hypercalcemia 
not attributable to other causes; (iii) severe and intractable pruritus; (iv) serum calcium–
phosphate product that consistently exceeds 5 mmol2/l2 together with progressive 
extraskeletal calcification; (v) progressive skeletal and articular pain, fractures or 
deformities; or (vi) calciphylaxis.62 
Data
Pre-dialysis serum chemistry samples were drawn monthly. Measurements were 
performed using standard methodology. Serum PTH, aluminum and Kt/V were 
routinely measured every 6 months. In individual cases, for example following changes 
in therapy, more frequent measurements were sometimes performed at the discretion 
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of the treating nephrologist. Intact PTH was measured with an IRMA (Nichols). The 
following data were analyzed: serum calcium, phosphate, albumin, PTH, alkaline 
phosphatase and Kt/V. Serum calcium was corrected for serum albumin.129 Means of 
all values during the first year of RRT per patient were used in order to define serum 
levels over time. 
Statistical analysis
Data are presented as means’s unless stated otherwise. For comparison between 
groups, a two-tailed Student’s t-test was used for continuous variables and chi-square 
analysis or Fisher’s exact test was used for discrete variables. Actuarial survival until need 
for PTx from the start of RRT was estimated with the Kaplan–Meier method. Patients 
were censored at the moment of renal transplantation, transfer to another centre, 
death or end of follow-up (August 2002), whichever occurred first without necessity 
for PTx at that point in time. Differences in survival time until PTx between groups were 
tested with the log-rank test. The following variables were tested: calcium, phosphate, 
calcium–phosphate product, alkaline phosphatase, intact PTH, Kt/V at the start and at 
1 year of RRT and the difference between both; the mean value of these parameters 
during the first year of RRT; type of initial RRT; gender; age; renal disease; years of renal 
disease before the start of RRT; and use of vitamin D at the start and after 12 months 
of RRT. Multivariate analysis with time to PTx as the dependent variable was performed 
with the Cox proportional hazards analysis. Only variables with a P-value of ≤0.10 by 
univariate analysis were included. A two-sided P-value of <0.05 was considered to 
indicate statistical significance. 
RESULTS
Patients
Between August 1988 and August 1996, 391 patients started RRT at our institution. 
Excluded from the analysis were 50 patients who underwent renal transplantation 
during the first year, 69 patients who died during the first year, 62 patients who were 
referred to another hospital within the first year, five patients who were younger than 
18 years at the start of dialysis and three patients who underwent PTx before or during 
the first year of dialysis. The data of the remaining 202 patients were entered into the 









Age (years) 54.9 ± 15.6 50.8 ± 14.5
Gender male 81 (57%) 32 (53%)
female 61 (43%) 28 (47%)
Renal disease glomerular 21 (15%) 11 (18%)
tubulo-interstitial 30 (21%) 14 (23%)
hypertension/vascular 20 (14%) 12 (20%)
diabetes 14 (10%) 9 (15%)
unknown/others 57 (40%) 14 (23%)
Length of renal disease (years)* 5.9 ± 6.5 6.6 ± 6.6
Vitamin D no 67 (47%) 25 (42%)
yes 75 (53%) 35 (58%)
Ca (Alb)  (mmol/l) 2.45 ± 0.25 2.50 ± 0.24
Ph (mmol/l) 1.98 ± 0.55 1.82 ± 0.43
Ca x Ph  (mmol2/l2) 4.53 ± 1.30 4.19 ± 1.00
PTH (pmol/l) 23 ± 22 19 ± 23
AP (U/l) 88 ± 48 89 ± 33
Values are expressed as number or means ± SD. Ca (Alb) = calcium corrected for albumin, Ph = phosphate, Ca 
x Ph = calcium phosphate product, PTH = parathyroid hormone, AP = alkaline phosphatase. *Documented 
in 140/202 patients.
Initial treatment modality was HD in 142 patients, of whom four switched to 
PD after 12 months (range: 3–28 months). PD was started in 60 patients, of whom 
35 switched to HD after 25±11 months. Mean follow-up was 45±25 months. During 
follow-up, 33/202 patients (16%) developed an indication for PTx after 52±23 months 
of RRT. PTx was needed in 18% of the patients who started with HD and 12% of those 
who started with PD. Of the remaining 169 patients, 77 received a renal transplant, 67 
died, 16 were transferred to another centre and nine were alive without needing PTx 
at the end of the study. 
Patients (15/44) with tubulointerstitial disease needed more frequent PTx as 
compared with the rest of the group (P<0.001), whereas patients with diabetes as the 
underlying cause for renal disease tended to need less frequent PTx (1/23; P = 0.14). 
Patients with tubulointerstitial disease had a significantly longer period of renal disease 
before the start of RRT (9.1±7.7 vs. 5.3±5.9 years; P = 0.015). 
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Biochemical values at the start and during the first year of RRT
The demographical, clinical and biochemical characteristics at the start of RRT are 
given in table 1. As compared with the start of RRT, phosphate was not different after 1 
year (1.93±0.53 vs. 1.88±0.45 mmol/l; P = NS). Mean phosphate during the first year was 
1.89±0.31 mmol/l and was >2.00 mmol/l in 31% of the patients. It exceeded 2.00 mol/l 
at some point during the first year in 37% of the patients. For HD-treated patients, a 
correlation between dialysis efficacy, measured as mean Kt/V during the first year, and 
mean serum phosphate was observed (r = –0.231, P = 0.007). 
Calcium was higher at 1 year as compared with the start of RRT (2.67±0.21 vs. 
2.47±0.25 mmol/l; P< 0.0001). Mean serum calcium–phosphate product during the 
first year of RRT was 4.85±0.81 mmol2/l2 and was <5.00 mmol2/l2 in 54% of the patients. 
It increased over the first year (4.43±1.23 vs. 4.97±1.21 mmol2/l2; P<0.001). None of the 
parameters differed significantly between HD- and PD-treated patients. 
PTH was >20 pmol/l at the start of RRT in 37% of the patients. In the pre-dialysis 
period, the percentage of patients treated with vitamin D analogues was less in 
patients starting RRT with a PTH >20 pmol/l (45% vs. 61%; P = 0.037). They also had a 
lower calcium (2.37±0.28 vs. 2.53±0.21 mmol/l; P<0.001), higher phosphate (2.05±0.56 
vs. 1.87±0.50 mmol/l; P = 0.022) and higher alkaline phosphatase (101±60 vs. 80±29 
U/l; P = 0.008) at the start of RRT as compared with patients who started with a PTH 
of <20 pmol/l. Duration of renal disease before the start of RRT, as documented in 
140/202 patients, was not different for both groups. Further information about pre-
dialysis treatment was not available. 
In 55% of the patients who started with a PTH >20 pmol/l, the level decreased 
to <20 after 1 year. In comparison with patients who maintained a PTH >20 pmol, 
they showed a lower PTH (40±21 vs. 51±23 pmol/l; P = 0.039) with a lower calcium 
(2.30±0.28 vs. 2.53±0.25 mmol/l; P = 0.015) at the start of RRT. They also had a larger 
increase of calcium during the first year (0.38±0.24 vs. 0.05±0.20 mmol/l; P<0.001). There 
was no difference in the number of patients that used vitamin D. In 9% of the patients 
who started with a PTH <20 pmol/l, the level increased to >20 pmol/l after 1 year. In 
comparison with patients who maintained a PTH <20 pmol/l, they showed a higher 
PTH at the start (12±5 vs. 8±5 pmol/l; P = 0.005) and tended to have a higher phosphate 
after 1 year (2.09±0.29 vs. 1.84±0.42 mmol/l; P = 0.057). Overall, the number of patients 
with a PTH >20 pmol/l was reduced to 42 (21%) at 1 year. In these 42 patients, 19 could 
not be treated with vitamin D due to unacceptable high calcium and/or phosphate 
levels. A strong correlation was found between the PTH at the start and after the first 
year of RRT (r = 0.56, P<0.001). 
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Analysis of predictive factors associated with need for PTx during follow-up
Thirty-three patients required PTx after 52±23 months of RRT. Survival without need 
for PTx was not different for patients with HD or PD as initial treatment modality. By 
univariate analysis, several parameters were found to be associated with the risk for 
PTx during follow-up (table 2). Most of these parameters reflected calcium–phosphate 
metabolism and levels of phosphate, calcium–phosphate product and PTH differed 
between patients with and without need for PTx (figure 1). Especially, phosphate >1.85 
mmol/l at 1 year of RRT (median value) was strongly associated with the need for PTx 
(figure 2). Multivariate analysis revealed that PTH, phosphate and alkaline phosphatase 
after 12 months of dialysis were independently associated with need for PTx during 
follow-up (table 3).
Table 2: Variables associated with a P-value < 0.10 by univariate analysis with time to need for PTx.
Variable Group definition P-value Relative Risk (95% CI)
Gender male / female 0.008 2.50 (1.28-5.26) a
Ca (Alb) (mmol/l) t0 ≤2.46, >2.46 0.020 3.23 (1.19-8.33) b
AP (U/l) t0 ≤80, >80 0.072 1.85 (0.94-4.00) b
AP (U/l) t1 ≤76, >76 0.056 2.00 (0.98-3.85) b
Ph t1 (mmol/l) ≤1.85, >1.85 0.006 2.63 (1.22-5.26) b
Ca x Ph t1 (mmol2/l2) ≤4.97, >4.97 0.015 2.33 (1.19-4.76) b
PTH t0 (pmol/l) ≤20, > 20 0.001 3.23 (1.79-7.69) c
PTH t1 (pmol/l) ≤20, > 20 <0.0001 5.56 (5.00-33.3) c
Relative risks are given for afemales compared to males; b the group with values above the median for the 
whole group compared to values below or equal to the median; c increased  compared with normal (≤ 20 
pmol/l)  levels of PTH. Abbreviations: Ca (Alb) = calcium corrected for albumin, AP = alkaline phosphatase, 
Ph = phosphate, PTH = parathyroid hormone, t0 = start of RRT, t1 = at one year of RRT.
Table 3: Variables independently associated with a P-value of <0.05 by multivariate analysis with 
time to need for PTx. Relative risks are given for the increase by one unit of the variable.
Variable P-value relative risk (95% CI)
Alkaline phophatase t1 (U/l) 0.049 1.004 (1.001 - 1.007)
Phosphate t1 (0.1mmol/l) 0.002 1.107 (1.035 – 1.183)
PTH t1 (pmol/l) <0.0001 1.018 (1.010 - 1.027)
CI = confidence interval; t1 = at one year of RRT
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Figure 1: PTH at start, one year of RRT and end of follow-up (A), and phosphate (B), calcium 
(C) and calcium-phosphate product (D) at start, 1 year of RRT and the mean value beyond 1 
year until the end of follow-up in patients who did (solid triangles) and did not (solid squares) 
need PTx. Horizontal error bars represent mean ± SD of duration of follow-up, vertical error bars 
represent the mean ± SD of the level of the parameter. *Differences with P<0.05 between both 
groups. 
Figure 2: Actuarial survival 
without need for PTx in 202 
patients according to phosphate 
<1.85 mmol/l (Ph <1.85; solid 
squares: n=103) or phosphate 
>1.85 mmol/l (Ph >1.85; solid 





Serum PTH, phosphate and alkaline phosphatase at 1 year of RRT were identified as 
independent variables associated with severe hyperparathyroidism leading to PTx 
during long-term follow-up. Although PTH decreased between start and 1 year of RRT 
and the fraction of patients with a PTH >20 pmol/l declined in this period, a substantial 
number (21%) of patients had persistent elevated PTH at 1 year of RRT. A failure to 
adequately control phosphate might have contributed to this. 
A few studies have identified predictive variables associated with severe 
hyperparathyroidism, but never specifically during the first year of dialysis in an 
unselected cohort. Mizumoto et al.135 found that initial PTH was a predictor of severe 
hyperparathyroidism, but PTH at 1 year was not analyzed as a potential risk factor. We 
observed that initial PTH was significantly associated with need for PTx by univariate 
analysis, but became statistically insignificant in the multivariate analysis due to the 
greater impact of PTH at 1 year. One year after the start of RRT seems to be a better time 
point, as in a substantial number of patients initially elevated PTH levels are corrected 
by correcting hypocalcaemia. Likewise, a strong association was found between 
phosphate levels at 1 year and need for PTx, but not at the start of RRT. 
Prevention of development or progression of sHPT should preferably start in the 
pre-dialytic period by dietary measures, phosphate binding and active vitamin D.132 
One of the factors associated with maintaining a PTH <20 pmol/l or reducing it to <20 
pmol/l during the first year of RRT was a lower PTH at the start of RRT. Patients with a 
lower PTH at the start of RRT used significantly more vitamin D. Patients who started RRT 
with a PTH >20 pmol/l combined with a low-normal calcium had a better chance to 
reduce their PTH to <20 pmol/l compared with patients with a high-normal calcium. It 
should be noted that a dialysate with a standard calcium concentration of 1.50 mmol/l 
was used, which might have had an effect on the correction of calcium. Patients with 
a high-normal calcium and PTH >20 pmol/l at the start may already have hyperplastic 
parathyroid glands with changes in setpoint and no longer respond adequately to 
vitamin D.130 This stresses the importance of early pre-dialysis correction and treatment 
of calcium–phosphate metabolism.136 
The strong predictors found in this retrospective study do not necessarily 
imply causality. Elevated PTH and alkaline phosphatase are a consequence of 
hyperactive parathyroids and a statistical correlation was expected. Instead, the 
strong relationship found between phosphate >1.85 mmol/l at 1 year of RRT and 
severe hyperparathyroidism might be causal. Hyperphosphathemia is associated 
with hyperplastic growth of the parathyroid glands, which may be related to the 
induction of parathyroid transforming growth factor-  expression.137 Phosphate also 
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regulates PTH in several ways. Hyperphosphathemia directly stimulates PTH synthesis 
and secretion by post-transcriptional mechanisms, induces skeletal resistance to PTH 
that decreases the release of calcium from bone, and inhibits the synthesis of active 
1,25(OH)
2
 vitamin D that is already low.137,138 In addition, serum phosphate of patients 
with a calcium–phosphate product >5 mmol2/l2 during the first year of RRT, as seen 
in 46% of the patients, was 20% higher than in patients with a product <5 mmol2/
l2, while calcium was only 4% higher. It seems, therefore, that phosphate is the major 
determinant of the calcium–phosphate product. An elevated calcium–phosphate 
product has been associated with increased mortality.139,140 Also, it has been suggested 
that elevated phosphate is the main contributor to the higher mortality risk associated 
with a calcium–phosphate product >72 mg2/dl2 and is associated with the increased 
risk for cardiac valvular surgery.139,141 Indeed, strict control of phosphate levels in the 
range 0.81–1.78 mmol/l (2.5–5.5 mg/dl) has recently been advocated to prevent 
cardiovascular disease in ESRD patients.142
New therapies, such as calcimimetic drugs, sevelamer and new vitamin D analogues, 
have recently been introduced to avoid increase of calcium–phosphate product, as 
often is the case with current therapy.143-145 Although these new therapies seem very 
promising in preventing severe hyperparathyroidism, long-term effects should be 
awaited. Chertow et al. 143 did not find an overall effect on the PTH level after treatment 
with sevelamer for almost 4 years in HD patients. Evaluating different dosage groups, 
they saw a reduced PTH, especially in the low dosage group representing patients 
with mild hyperphosphathemia. This means that, especially, patients at an early stage 
of disease might benefit more from treatment with sevelamer. The new vitamin D 
analogue paricalcitol was shown to be effective in lowering PTH without hypercalcemia 
during 13 months of follow-up and recently was found to be associated with a better 
survival as compared with calcitriol.146,147 Long-term effects of calcimimetic agents are 
not available yet. Experimental studies should evaluate whether these new therapies 
reduce severe hyperparathyroidism during long-term follow-up in high-risk patients at 
an early stage of disease.
CONCLUSION
Serum PTH, phosphate and alkaline phosphatase after 1 year of RRT were found to 
be independent predictors of severe hyperparathyroidism needing PTx. Patients at 
high risk for PTx during long-term follow-up can be identified by these parameters at a 
relatively early stage. Pre-dialysis correction of the calcium–phosphate metabolism as 




Incidence and prognosis of parathyroid gland 
carcinoma:  a population-based study in The 
Netherlands estimating the preoperative diagnosis
M. Schaapveld1, F.H. Jorna2, K.K.H. Aben3,4, H.R. Haak5, J.T.M. Plukker2, T.P. Links6
1Comprehensive Cancer Center North-East; Groningen
2 Department of Surgical Oncology, University Medical Center Groningen, Groningen
3Comprehensive Cancer Center East; Nijmegen 
4Department of Epidemiology, Biostatistics and Health Technology Assessment, Radboud 
University Nijmegen, Nijmegen 
5 Department of Internal Medicine, Maxima Medical Center, Eindhoven
6Department of Endocrinology, University Medical Center Groningen, Groningen
The Netherlands




Introduction: Parathyroid carcinoma is a rare malignancy and generally is diagnosed 
after surgery for primary hyperparathyroidism (pHPT). Lack of a preoperative diagnosis 
and ill-considered surgical planning with its impact on survival are ill-described. 
Methods: In a retrospective population-based cohort study the clinical features, 
treatment, recurrences, and survival of 41 parathyroid cancer patients are reported 
and compared with characteristics of patients with pHPT.
Results: Patients with parathyroid carcinoma had significantly higher serum 
parathyroid hormone and calcium levels compared with patients with pHPT. Nineteen 
patients (46%) had a palpable neck mass. A parathyroid hormone level more than 3 
times the upper normal limits was suspicious and levels more than 10 times carried a 
positive predictive value of 84% for carcinoma. Ten-year recurrence-free and disease-
specific survival rates were 71% and 79%, respectively. 
Conclusion: Parathyroid hormone levels of more than 3 times upper normal limits, 
palpable neck mass, and profound hypocalcemia are suspicious signs of carcinoma 




Carcinomas of the parathyroid gland are very rare tumors.148 Their etiology is unknown, 
although recent studies have suggested an important role for the HRPT2 gene (1q25-
31).149,150 HRPT2 gene mutations usually are found in combination with pHPT and 
the jaw tumor syndrome. Parathyroid carcinomas are generally hyperfunctioning, 
accounting for only 0.5% to 5% of all patients with hyperparathyroidism.151-153 Less 
than 10% of patients have no clinical manifestations of hyperparathyroidism and 
about 50% of all patients present with a palpable tumor in the neck, kidney stones, or 
osteoporosis.148,151 Compared with patients with benign primary parathyroid disease, 
parathyroid hormone (PTH) and serum calcium levels are generally higher among 
parathyroid carcinoma patients.148,153 
Parathyroid carcinoma is commonly diagnosed after surgery for pHPT, when the 
removed tumor shows malignant features at pathologic examination. However, the 
histologic distinction between parathyroid adenoma and parathyroid carcinoma 
can be difficult because adenomas also may show mitotic activity and even capsular 
invasion.148,154 Direct extension in surrounding tissues, vascular invasion, and metastasis 
are nonetheless clear signs of carcinoma. The clinical behavior of parathyroid carcinoma 
can vary from an indolent to a more aggressive course with recurrent disease in up to 
79% of cases.151-155 In a recent review article, Talat and Schulte156 described a group of 
patients with a 3.5-fold to 7.0-fold higher risk for recurrence and death.
Radical surgical resection is the only effective treatment modality, determining 
the prognosis of these patients. Therefore, it is desirable to distinguish benign 
from malignant disease before surgery. Unilateral central compartment dissection, 
consisting of a wide unilateral en bloc dissection of the parathyroids with ipsilateral 
hemithyroidectomy and central lymph node clearance, appears to give the best 
chance of locoregional tumor control.151 Chemotherapy and radiotherapy have no 
clear role in the treatment of parathyroid carcinoma, although in a small patient series 
the absence of locoregional recurrences has been attributed to the effect of adjuvant 
radiotherapy.155
The Netherlands Cancer Registry offers a unique opportunity to study this rare 
malignancy in detail in a population-based setting because the regional cancer 
registries have access to the medical files of cancer patients in The Netherlands. We 
report the incidence, treatment, and relapse-free and disease-specific survival of 
patients with parathyroid carcinoma in The Netherlands. Furthermore, we compare 
the clinical presentation of parathyroid carcinoma patients with a cohort of patients 
with solitary benign parathyroid disease to distinguish clinical features associated with 





All patients diagnosed with parathyroid gland carcinoma in The Netherlands between 
1989 and 2003 were selected from The Netherlands Cancer Registry. It has had 
complete coverage since January 1989. The regional cancer registries contributing 
to The Netherlands Cancer Registry were requested to collect additional information 
on cases recorded by their registry directly from the patient’s medical records and 
provide follow-up information. Eligible cases were primary malignant carcinomas 
of the parathyroid gland (International Classification of Diseases, 10th edition, 
194.1; International Classification of Diseases for Oncology C75.0 and morphology 
M8000/3-M8576/3).
Forty-three patients initially were selected. Two patients were excluded from 
analysis after chart review. One patient was diagnosed with extrathyroidal thyroid 
carcinoma after pathologic review and in the other patient parathyroid carcinoma was 
suspected but never confirmed pathologically, despite repeated neck dissections for 
recurrent hyperparathyroidism. This patient was lost to follow-up evaluation in 1997. In 
1 of the remaining 41 patients the diagnosis was confirmed histologically at autopsy. 
Two patients were lost to follow-up evaluation before 2004 (1993 and 1997 with 4.0 
and 6.4 years of follow-up evaluation, respectively). Information on type of resection, 
secondary exploration, and on radiotherapy dose and fractionation were not recorded. 
Although postoperative PTH levels were requested, these data unfortunately were not 
recorded uniformly.
Benign primary hyperparathyroidism
For the patients with benign pHPT, data were retrieved from a database containing 
preoperative information on 200 consecutive patients who underwent surgery for 
primary benign parathyroidism between 1990 and 2003 in the University Medical 
Center Groningen, a tertiary referral center in the North Netherlands and the Martini 
Hospital in Groningen, a large teaching hospital affiliated with the University Medical 
Center Groningen. In 185 of 200 patients surgery was successful. Of these patients 164 
had a solitary adenoma, 14 had a double adenoma, and 7 had hyperplastic disease. For 
the analysis we only used the preoperative data of the patients with solitary adenomas.
Statistical analysis
Patients were staged as having localized disease, invasion into adjacent structures, 
regional nodal extension, or distant metastasis. Comparison between the groups was 
performed with a Mann–Whitney test for continuous variables; the chi-square or Fisher 
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exact test was used for comparison of categoric variables. The ability of PTH, calcium, 
and creatinine levels to differentiate parathyroid carcinoma from benign pHPT was 
explored using area under the curve receiver operating characteristics (AUC-ROC) 
analysis and logistic regression analysis. Biochemical data were expressed as the upper 
limit of normal using upper limits from each individual hospital laboratory. Cut-off 
values for parathyroid hormone, calcium, and creatinine levels were determined based 
on the Q-point (the point at which sensitivity equals specificity) of the ROC. Disease-
free survival was defined as the interval between diagnosis and first relapse, whether 
local or distant. Disease-specific survival was defined as the interval between diagnosis 
and death from parathyroid carcinoma or death with parathyroid carcinoma. Patients 
who died without parathyroid carcinoma recurrence were censored in this analysis. 
The 5- and 10-year disease-free and disease-specific survival were estimated using 
Kaplan-Meier methods and univariable comparisons of survival time by covariate 
patterns were evaluated using the log-rank test. Cox proportional hazards analysis was 




Table 1 shows the clinical features of all 41 patients diagnosed with parathyroid 
carcinoma between 1989 and 2003. The median age at diagnosis was 62 years, and 
age did not differ between men and women (median age, 55.6 and 66.0 y, respectively; 
P=0.184). Preoperative calcium level was increased in 38 patients. Of all 41 patients, 1 
patient had PTH levels within the upper normal limits and 34 patients presented with 
hyperparathyroidism. In 6 patients the presence of hyperparathyroidism was unknown. 
One of these patients initially presented with metastasis of unknown origin, another 
patient underwent surgery with a diagnosis of thyroid carcinoma, and 3 patients were 
admitted with severe hypocalcemia. The remaining patient was admitted with slight 
hypocalcemia and a history of renal stones. Nineteen patients (46.3%) had a palpable 
neck mass at presentation.
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Table 1: Patient and tumor characteristics and univariate comparisons for disease-free and 
disease-specific survival
Patients Disease free survival# (%) Disease specific survival (%)
N % 10-year p-value* 10-year p-value*
Sex 0.314 0.841
   Male 21 51.2 62.9 81.0
   Female 20 48.8 82.4 74.8
Age 0.661 0.682
   <50 12 29.3 62.5 81.5
   50-64 15 36.6 65.5 72.7
   65+ 14 34.2 83.3
Tumor palpable 0.554 0.186
   Yes 19 46.3 61.8 66.4
   No 15 36.6 78.6 85.7
   Not stated 7 17.1 66.7 100.0
Lateralisation 0.610 0.663
   Left 19 46.3 63.1 75.8
   Right 19 46.3 75.5 88.2
   Unknown/ not specified 3 7.3 100.0 100.0
PTH (pmol/l)‡ 0.276 0.686
   <3*ULN 5 12.2 100.0 100.0
   3-9*ULN 11 26.8 70.0 80.0
   ≥10*ULN 16 39.0 45.8 71.1
   unknown/ not done¶ 9 22.0 87.5 77.8
Calcium (mmol/l) <0.001 <0.001
   Normal 2 4.9 0.0 0.0
   >1-1.4*ULN 34 82.9 82.6 86.6
   ≥1.5*ULN 4 9.8 0.0 75.0
   Unknown/ not done 1 2.4 0.0 0.0
Serum creatinine (μmol/l) 0.018 0.651
   <100 18 43.9 94.1 88.5
   100-199 13 31.7 65.6 74.1
   200+ 6 14.6 25.0 66.7
   Unknown/ not done 4 9.8 66.7 75.0
Renal symptoms 0.231 0.413
   YesÔ 11 26.8 90.0 90.0
   No 30 73.2 64.6 75.4
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Patients Disease free survival# (%) Disease specific survival (%)
N % 10-year p-value* 10-year p-value*
   Yesà 10 24.4 62.5 66.7
   No 31 75.6 74.3 83.8
Extend of disease 0.163 <0.001
   Localized 25 61.0 80.8 85.6
   Invasion adjacent organs 9 22.0 50.9 88.9
   Invasion & regional nodes 1 2.4 0.0
   Regional nodes 1 2.4
   Distant metastaseså 2 4.9 -
   Not stated 3 7.3 66.7 100.0
Free resection margins, 
no tumorspill$
0.002 0.088
   Yes 20 50.0 90.0 90.0
   No 14 35.0 26.9 59.5
   Unknown/ not stated 6 15.0 100.0 100.0
*    p-value based on long rank test 
#   excluding two patients with metastasis at diagnosis 
$    excluding one patient who was not operated 
‡    various PTH assays were used since 1989
¶    three patients with hyperparathyroidism without PTH levels stated in the charts, three patients with 
(severe) hypocalcaemia, one patient who underwent surgery for thyroid carcinoma after which pathology 
revealed parathyroid carcinoma,  one patient with metastatic carcinoma; post mortem pathology shows 
parathyroid carcinoma. The remaining patient had a history of renal stones and now presented with slight 
hypocalcaemia.
Ô  kidney colic (3), nephrolithiasis (2), nephrocalcinosis (1), decreased kidney function (4)     nephrolithiasis 
and decreased kidney function (1)
à   bone pain (8), osteoporosis (1), unspecified (1) 
å   lung (2), liver (1) 
Preoperative differentiation of parathyroid carcinoma and solitary parathyroid 
adenoma
In Table 2 the clinical presentation of patients with parathyroid carcinomas is compared 
with patients who underwent PTx for benign pHPT as a result of a solitary adenoma. 
Although solitary adenomas occur more often in females, the incidence of parathyroid 
cancer was evenly matched between the sexes. There was no difference in age at 
time of surgery and in the frequency of renal and skeletal involvement, but a palpable 
mass in the neck was strongly suggestive for parathyroid carcinoma when coinciding 
with hyperparathyroidism or hypocalcemia. Serum parathyroid hormone levels and 
calcium concentrations were significantly higher among patients with parathyroid 
carcinoma, as was the serum creatinine level. Log-transformed serum PTH and serum 
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calcium were correlated (Spearman ρ=0.49; p<0.0001), as were transformed serum 
PTH and creatinine levels (Spearman ρ=0.31; p<0.0001). The AUC-ROCs for PTH and 
calcium (measured relative to the upper normal limits) and creatinine were 88.7 (95% 
confidence interval [95% CI], 81.3–96.0), 79.3 (95% CI, 70.2– 88.4), and 64.1 (95% CI, 51.9 
–76.4), respectively. AUCs did not differ between serum PTH and calcium (P=0.234), 
but both PTH (P=0.007) and calcium (P=0.107) as single tests performed better than 
serum creatinine. The Q-point for serum PTH was about 3 times the laboratory upper 
normal limit and for calcium was 1.15 times the upper normal limit (Table 3). A PTH 
level 10 times or more the upper normal limit was highly predictive for parathyroid 
carcinoma (positive predictive value, 84.0%).
Combining serum calcium and serum PTH (both log transformed) in a multivariate 
logistic regression analysis only slightly increased the predictive power (AUC, 90.1; 
P=0.050) of serum PTH alone. Adding creatinine to the model did not improve 
predictions further (AUC, 90.3; P=0.187).
Table 2: Comparison of patient and tumor characteristics including preoperative PTH, serum 









Female: male ratio 2.81  :  1 1.05  : 1 .002
Median age, y ( IQR) 59 (49.0-69.0) 62 (44.8-72.1) .958
Tumor palpable 0 19 (46.3%) <.0001
Symptoms of bone disease 35 (26.1%) 10 (24.4%) .825
Symptoms of Renal disease 39 (29.1%) 11 (26.8%) .778
Median PTH level, pmol/l (IQR) 17.0 (11.5-25.0) 78.0 (29.7-121.5) <.0001
Median PTH level, ULN (IQR) 1.64 (1.09-2.50) 10.23 (4.02-16.79) <.0001
Median serum calcium level, mmol/l (IQR) 2.92 (2.77-3.10) 3.26 (3.00-3.45) <.0001
Median serum calcium level,  ULN (IQR) 1.09 (1.03-1.15) 1.24 (1.15-1.34) <.0001
Median creatinine level, μmol/l (IQR) 83 (73-99) 118 (78-186)  .0007
IQR = interquartile range; ULN = upper limit of normal.
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Table 3: Univariate test characteristics of serum calcium and serum PTH for prediction of 








false positives false negatives Sensitivity Specificity
Serum calcium level *
   Calcium ≥1.10 ULN 70 8 80.0% 56.3%
   Calcium ≥1.15 ULN 38 9 77.5% 76.3%
   Calcium ≥1.20 ULN 20 15 62.5% 87.5%
   Calcium ≥1.25 ULN 11 22 45.0% 93.1%
   Calcium ≥1.35 ULN 4 31 22.5% 97.5%
Serum PTH level **
   PTH ≥1.50 ULN 87 2 93.8% 43.9%
   PTH ≥3.00 ULN 31 5 84.4% 80.0%
   PTH ≥4.50 ULN 16 9 71.9% 89.7%
   PTH ≥6.00 ULN 8 13 59.4% 94.8%
   PTH ≥7.50 ULN 6 14 56.3% 96.1%
   PTH ≥10.00 ULN 2 15 53.1% 98.7%
ULN = upper limit of normal.
* Calcium known for 160 patients with solitary parathyroid adenoma and 40 patients with parathyroid 
carcinoma   
** PTH known for 155 patients with solitary parathyroid adenoma and 32 patients with parathyroid carcinoma 
Initial treatment
Four patients (9.8%) had a preoperative histologic diagnosis of parathyroid carcinoma 
(3, 4, 5, and 51 days before surgery, respectively). All but 1 patient underwent tumor 
resection and 5 patients received adjuvant radiotherapy. None of the patients received 
chemotherapy. In 14 patients the initial resection was incomplete or complicated 
by tumor spill. Of the 5 patients who received adjuvant radiotherapy, 3 patients had 
a microscopic incomplete resection and in 1 patient tumor spill had occurred. The 
remaining patient had an incomplete initial resection followed by a complete re-
resection with neck exploration and postoperative radiotherapy. For only 23 patients 
postoperative PTH levels were known, in 8 patients PTH levels remained increased. 
High postoperative PTH level was not correlated with completeness of resection 




The median follow-up period was 6.6 years (interquartile range, 4.0 –10.7 y). Ten 
patients relapsed during the follow-up period, other than the 2 patients who already 
presented with distant metastasis at diagnosis (Table 4). The 5- and 10-year disease-
free survival were 79.0% and 70.8%, respectively.
Three patients had a locoregional relapse, 2 patients developed distant metastasis 
and 5 patients had both locoregional and distant recurrence. Distant metastasis 
occurred in the lung (6), bones (1), and brain (1). The median time between diagnosis 
and recurrence was 2.3 years (interquartile range, 1.1–3.7 y). The median survival after 
relapse was 2.0 years. Four of the 5 patients treated with adjuvant radiotherapy suffered 
local as well as distant relapses.
For 1 patient a recurrence could not be proven although the PTH levels remained 
very high (>3 to 10 times the upper normal limit) during follow-up evaluation. This 
patient was alive without tumor recurrence 10.7 years after presentation.
Disease-specific survival
During the follow-up period 15 patients died. Eight patients died because of 
complications of metastatic parathyroid carcinoma (Table 4), among them were 3 
of the 5 patients treated with adjuvant radiotherapy. In the remaining 7 patients the 
cause of death was unknown in 5 patients, although probably was age-related (age at 
death: 79, 83, 85, 86, and 89 y). One patient died of an accident and another patient 
died of prostate cancer. These 7 patients had no evidence of disease recurrence during 
follow-up evaluation.
The 5- and 10-year disease-specific survival were 82.5% and 78.9%, and the 5- and 
the 10-year overall survival were 80.4% and 68.0%, respectively.
Prognostic factors
The most important predictor of relapse was tumor-involved resection margins and/
or perioperative tumor spillage (hazard ratio, 5.5; 95% CI, 1.1–27.1). In multivariate Cox 
regression, besides incomplete surgery a serum creatinine level of more than 200 
μmol/l was associated with increased risk of relapse (hazard ratio, 12.7; 95% CI, 1.3–
119.4). Only stage was associated with disease-specific survival. All 4 patients who had 


































































































































































































































































































































































































































































































































































































































































































































































































































































































Parathyroid carcinoma is an extremely rare tumor with an incidence of 1.25 per 
10,000,000 per year. In a 15-year period only 41 parathyroid cancer patients were 
diagnosed in The Netherlands. In this series the presence of a palpable neck mass 
concomitant with hyperparathyroidism or hypocalcemia was highly suggestive for 
parathyroid carcinoma. Especially high serum PTH and calcium were predictive for 
the occurrence of parathyroid carcinoma. We advise referring patients with serum 
PTH levels greater than 3.0 times the upper normal limit and serum calcium levels 
greater than 1.15 times the upper normal limit to a specialized center. Expert surgeons 
should perform surgery focusing on intraoperative signs of parathyroid cancer. Besides 
local invasive growth or metastatic nodal involvement, parathyroid carcinoma can be 
recognized intraoperatively as a macroscopically large, hard, whitish tumor surrounded 
by fibrous tissue, whereas adenomas tend to be soft, round, or oval with a reddish-
brown color.148,157 If the presence of carcinoma is suspected, primary en bloc resection 
of the ipsilateral parathyroid glands with the surrounding hemithyroid and lymphatic 
tissues, including an unilateral/ipsilateral central compartment, should be considered 
because it has been associated with prolonged disease-free survival.151,158 Compared 
with simple PTx this procedure provided a lower local failure and higher long-term 
survival rate in patients with a tumor of relatively low malignancy and may prevent 
recurrent disease in more aggressive lesions.158
Certain clinical features, including very high preoperative calcium and PTH serum 
levels, a palpable cervical mass, unilateral vocal cord paralysis, and the presence of 
both renal and skeletal disease have been associated with parathyroid carcinoma. They 
may be useful to distinguish carcinomas from adenomas preoperatively,148,159-162 but in 
this study we further quantify PTH and calcium levels to support a surgical decision. 
Because preoperative aspiration cytology or core biopsy are contraindicated because 
of the associated risk of tumor seeding, these clinical observations are important 
given the difficulty of establishing a preoperative diagnosis of parathyroid carcinoma. 
Although DNA mutational analysis may be helpful in the identification of malignant 
disease, it still has low clinical relevance for the individual patient.
Busaidy et al163 found that 70% of tumors showed local invasion, which may lead to 
a high rate of irradicality and local recurrences. As shown in Table 1, 25 patients (61%) 
in our cohort were diagnosed with localized disease, of whom 4 developed recurrent 
disease, 1 after preoperative tumor spill and 2 patients owing to an initially nonradical 
resection. It is likely that only 23 patients (56.1%) truly had localized disease. In our 
cohort 12 of the 41 patients (29%) presented with or developed recurrent disease, 
either at diagnosis or after a median follow-up period of 6.5 years. In the MD Anderson 
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series, 6 (23%) of the patients developed distant metastasis and 11 (41%) patients 
relapsed locally or regionally after an average follow-up period of 7.9 years.163 However, 
in another single-institution case series presented by Iacobone et al,153 all 19 included 
patients experienced tumor recurrence and 84% developed distant metastases. There 
may be a possibility of selective referral in their study, which may have resulted in a 
case series strongly selected on prognosis. In the study by Kleinpeter et al,152 5 (22%) 
of 23 patients developed recurrent tumor after a median follow-up period of 11.2 
years. These figures are more in line with the relapse rate in our study, especially when 
considering the long follow-up results in both series. We observed a 10-year disease-
free survival of 79%, which is somewhat higher compared with survival rates reported 
in previous studies. However, these studies were generally based on smaller numbers 
and selected sets of patients, which might explain these difference.151,152,154,155,162 After 
development of distant tumor recurrence survival is fairly poor. At the end of the study 
only 1 of the patients with metastatic disease was alive compared with all 3 patients 
suffering from isolated local tumor recurrence.
In our cohort 4 of the 5 patients who received adjuvant radiotherapy experienced 
tumor recurrence, of whom 3 died. These data are in contrast to findings from 
Munson et al,155 who reported no evidence of disease in all 4 patients who received 
adjuvant radiotherapy, provoking the statement that radiotherapy may result in a 
lower risk of locoregional disease progression and improved cause-specific survival. 
Adjuvant radiotherapy was administered to patients who had either a nonradical initial 
resection or in case of perioperative tumor spill. Based on our findings, expectations 
toward adjuvant radiotherapy should be tempered. However, immunotherapy may 
hold promise for adjuvant treatment of parathyroid carcinoma because a recent study 
showed a significant antitumor effect after PTH immunization.164
Similar to all other studies, our study was retrospective in nature and had some 
inherent strengths and weaknesses. Because it was population-based it did not suffer 
from selection or referral bias. Furthermore, comparing features of patients with pHPT 
and parathyroid carcinoma over the same period results in clinical practical advice 
regarding serum calcium and PTH levels. A concern when studying incidence and 
survival in these rare tumors is the inaccuracy of diagnosis and incompleteness of 
registration. Ideally, one would re-assess the pathology of all registered cases, and 
for a suitably large sample of parathyroid adenomas diagnosed in the same period. 
With regard to the excellent disease-free and disease-specific survival for patients with 
relatively low PTH level increase, it is possible that some of these cases were tumors 




Clinicians should be alert for parathyroid carcinoma in patients with marked increased 
PTH levels (>3 times upper normal limits), profound hypocalcemia, and/or a palpable 
neck mass. The rarity of this disease requires treatment by experienced endocrine 
surgeons, preferably in a center of excellence in (para)thyroid surgery.
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Summary, general discussion and future perspectives
In the general introduction in chapter 1, epidemiological, pathophysiological, and 
therapeutical aspects of hyperparathyroidism are discussed. In the following chapters 
different tools are described that may be helpful in planning the surgical approach, 
guiding the surgery and confirming  the surgical success during the operative process. 
Tools discussed are preoperative imaging by means of 99mTc-Sestamibi scintigraphy, 
intraoperative use of the gammaprobe and intraoperative PTH monitoring. The last 
chapters describe the risk factors for secondary hyperparathyroidism (sHPT) needing 
parathyroidectomy (PTx) among dialysis patients and the risk factors for parathyroid 
carcinoma among patients presenting with primary hyperparathyroidism (pHPT) as 
well as the incidence and prognosis of parathyroid carcinoma.
Preoperative parathyroid imaging
Accurate preoperative localization of hyperactive parathyroid (PT) glands is important 
in the surgical treatment of HPT and in particular pHPT, to identify unusual or ectopic 
lesions and to provide information to determine if minimally invasive surgery is 
appropriate.15,165 99mTc-Sestamibi scintigraphy is generally the imaging modality 
of choice for preoperative localization. A combination of different scintigraphy 
techniques may improve sensitivity, but is a time- and cost-consuming procedure. In 
chapter 2 the relative contributions of single photon emission computed tomography 
(SPECT) and 123I-subtraction in addition to planar 99mTc-Sestamibi scintigraphy were 
evaluated in both pHPT and sHPT. Therefore 111 consecutive patients who underwent 
preoperative planar 99mTc-Sestamibi  scintigraphy were evaluated,  64 patients who 
underwent delayed SPECT, and 17 patients who underwent 123I-subtraction. 
Planar scintigraphy had a sensitivity of 77% for adenomas with a positive predictive 
value (PPV) of 83%. SPECT did not improve these results, but increased the confidence 
of the readers and thereby beneficially changed the surgical management in 21% of the 
patients. SPECT improved the contrast and provides 3-dimensional visualization, which 
may be useful in planning of minimal invasive surgery even in vague solitary lesions on 
the planar scan. SPECT was helpful in detecting adenomas in the tracheoesophageal 
region and ectopic retroesophageal region. The supposed advantage of adding 
123I-subtraction imaging is preventing false positive findings by 99mTc-Sestamibi uptake 
in thyroid nodules and detecting glands with a fast washout of 99mTc-Sestamibi.15,30,30 
123I-subtraction imaging was evaluated in a small group. It increased the sensitivity for 
adenomas, but decreased the PPV. It may be considered in pHPT if other studies are 
negative. Our findings showed that SPECT can be valuable in addition to planar 99mTc-
Sestamibi  scintigraphy for detecting parathyroid adenomas in pHPT, by localizing 
ectopic glands, improving diagnostic confidence and the surgical strategy. 
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For hyperplastic glands, 99mTc-Sestamibi  scintigraphy had a sensitivity of 47% and 
a PPV of 95%. SPECT and 123I-subtraction imaging did not substantially improve these 
results. Therefore we consider that there is no place for preoperative scintigraphy in 
the primary surgical treatment for sHPT. However, it has been reported valuable before 
performing redo surgery in residual disease.10,19 
Other non-invasive preoperative modalities for imaging the parathyroid glands 
include ultrasound, contrast enhanced multidetector computed tomography (MDCT), 
magnetic resonance imaging (MRI) and positron emission tomography (PET) or 
combinations of techniques. Ultrasound is used in some centers as first choice modality 
but has several drawbacks. The diagnostic accuracy is highly operator dependent, it 
has a limited field of view resulting in a low sensitivity for localizing ectopic glands and 
exploration is difficult in the presence of goiter. Reported sensitivities vary between 
44% and 87%.49 MRI, CT and PET scan have yet been advised as second line imaging 
modalities in case of negative or doubtful results with scintigraphy and in case of 
persistent or recurrent hyperparathyroidism.
MRI provides high spatial resolution with superior tissue contrast compared to 
MDCT without the use of ionizing radiation and iodinated nephrotoxic contrast 
materials. Drawbacks of MRI imaging include long examination times, frequent 
presence of movement artifacts, higher cost and less availability compared to CT. 
Reported sensitivities of MRI vary widely between 42-88%.51,52,52,53
Computed tomography provides excellent anatomical detail. Sensitivity rates 
range from 35 to 71% before initial surgery.166,167 MDCT acquires multiple slices in 
seconds providing ≤1 mm slices. Sensitivities with 16 or 64-slice MDCT in pHPT range 
from 46%-88%.168 However sensitivity in patients with pHPT caused by multi glandular 
disease was only 17%.168 Our experiences with a 16-slice MDCT showed a sensitivity 
of 75% in pHPT (data not presented in this thesis), and are in line with these reports. 
Currently 64-slice MDCT is used in the UMCG. In selected patients with pHPT and 
negative scintigraphy or ultrasound results, sensitivities of 78-86% are reported with 
MDCT.166,169 The novel 4D-MDCT technique that uses differences in parathyroid gland 
perfusion characteristics as a surrogate indicator of function, had a sensitivity of 82%-
88% in patients before redo surgery 170,171 MDCT seems most valuable as a second-line 
imaging modality. 
The desire to combine detailed anatomic and functional information has led to 
the introduction of SPECT/CT software- and hardware fusion techniques in the recent 
decade. Currently various SPECT/CT devices are commercially available ranging from 
simple CT add-on to a conventional SPECT system that can provide low-dose CT 
images to a full multi-detector CT (MDCT) scanner integrated with a SPECT system.172 
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Low dose CT images are useful for CT-based attenuation correction that allows 
superior quantification of radiotracer uptake. Several studies report an increased value 
of SPECT/CT over conventional scintigraphy, especially by reducing false positive 
findings173, detecting ectopic glands or identifying multiglandular disease in pHPT 
33,174-178 However, others claim little benefit additional to conventional SPECT.55,179,180 
Further studies are needed to establish the role, optimal technique, costs and costs-
effectiveness of SPECT/CT.
11C-methionine-PET is a not commonly available second line imaging method to 
identify hyperactive parathyroids. The radiopharmaceutical 11C-methionine has been 
considered to improve diagnostic yield due to a higher specificity compared to other 
radiotracers. 11C-methionine is considered to be very specific, since synthesis of the 
PTH precursor hormone pre-pro-PTH comprises seven methionines and stimulates 
amino acid influx into parathyroid tissue.181 In a limited number of retrospective cohort 
studies sensitivities ranged from 33-94% for pHPT and from 39-69% for sHPT mainly in 
selected patients with inconclusive or negative conventional imaging and/or residual 
HPT.181-183 Reported sensitivities with hybrid imaging with PET-CT are 83-90% for pHPT 
and 63% for sHPT.184,185 The clinical value of 11C-methionine-PET/CT has yet to be 
determined in prospective studies. 
In our tertiary referral hospital, the University Medical Center Groningen (UMCG), 
nowadays standard planar 99mTc-Sestamibi scintigraphy with 99mTc-pertechnetaat 
subtraction is combined with SPECT/(low dose)CT as first choice modality for patients 
with pHPT. In case of residual disease and/or negative scintigraphy a MDCT, MRI or 
11C-methionine-PET/CT are used as second line imaging modality. We are awaiting the 
analyses of the current protocol as well as the results of 11C-methionine-PET/CT in a 
selected group of patients. As a tertiary referral center for the northern part of the 
Netherlands, we are in the position to conduct a prospective study evaluating the 
second line imaging modalities in our hospital for patients with negative scintigraphy 
results or residual HPT. 
Radioguided parathyroidectomy
The gammaprobe has been demonstrated useful during PTx for pHPT in two ways. 
It guides the surgeon during (minimal invasive) surgery. Secondly, it confirms the 
presence of an adenoma if radioactive counts in the resected tissue are greater than 
20% of the background counts in the wound bed.13 The role of radioguided surgery in 
sHPT is however unclear. In chapter 3 the results were presented of our prospective 
study, concerning the usefulness of radioguidance during PTx for sHPT. The value 
of the probe was determined in 29 patients with secondary or tHPT. The probe was 
Chapter 8
94
helpful in guiding resection in just 13% of the hyperplastic glands. However it detected 
4 out of 10 ectopic glands, that were not detected on preoperative scintigraphy. The 
probe confirmed the presence of hyperplastic glands after resection with a sensitivity 
and specificity of 97% and 92%, respectively. Therefore, the gammaprobe is useful in 
confirming the presence of hyperplastic glands after resection, despite low sensitivity 
of preoperative 99mTc-sestamibi scintigraphy (47%)186. Its use in guiding the resection 
during bilateral exploration is quite limited, but it can be useful in identifying ectopic 
localizations. As 99mTc-Sestamibi uptake reflects the degree of suppressibility and 
autonomy of a gland, the probe can be helpful in choosing the parathyroid gland 
most suitable for autoimplantation.187,188 
Nowadays in the UMCG, we recommend no preoperative imaging for patients with 
sHPT or tHPT needing primary surgery, except for ultrasound of the neck to identify 
possible thyroid nodules that may be responsible for false positive results with the 
gammaprobe. Approximately one hour before PTx the patient is injected with 99mTc-
Sestamibi. The gammaprobe is used routinely for affirming hyperplastic parathyroid 
tissue after resection, omitting frozen section analysis and selecting the appropriate 
gland for adequate autoimplantation. If less than four glands are identified at the usual 
anatomic sites, the gammaprobe may be helpful in localizing an ectopic gland.
Although not widely used, we have observed clear benefits of the radioguided 
approach as described by others.62,67,189 Nichol et al reported significant reduction of 
operative times of radioguided PTx in this patient group, as compared to a historical 
control group.67 This could lead to a reduction of costs. However, no study has 
been reported so far evaluating the cost-effectiveness of the gammaprobe in sHPT. 
Therefore we should evaluate the cost-effectiveness using the available data on the 
gammaprobe and compare those with a historical control group. 
Is there an option for enhancing 99mTc-Sestamibi results?
99mTc-Sestamibi is the radiotracer mostly used for pre- and intraoperative imaging 
of the parathyroids,  but the exact mechanism of retention of this compound in 
parathyroid tissue is unknown. Differences in the sensitivity for adenomas and 
hyperplastic glands cannot solely be explained by size. In chapter 4 the possible role 
of the proteins P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 
(MRP1) was evaluated in the retention of 99mTc-Sestamibi in the parathyroids. Both 
are transmembrane efflux pumps that are able to transport 99mTc-Sestamibi over 
membranes and may determine the amount of retention of 99mTc-Sestamibi. Available 
inhibitors of P-gp may enhance results of parathyroid imaging. 
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We studied 33 patients that underwent radioguided PTx. In total 23 adenomas, 
36 hyperplastic glands and 4 normal parathyroid glands were resected. After routine 
histology, immunohistochemistry was performed on the excised glands. A semi 
quantitative scoring system for P-gp and MRP1 expression was used, covering both 
the distribution of positive cells and the intensity of immunostaining. The outcome 
was related to preoperative 99mTc-Sestamibi dual-phase and SPECT results, histology, 
weight and amount of decay corrected radioactivity of the gland as measured by the 
gammaprobe intraoperatively. We found that P-gp staining was positive in 91% of 
the adenomas and 100% of the hyperplastic glands. MRP1 staining was positive in 
22% of the adenomas and in 61% of the hyperplastic glands. However we found no 
correlation between the expression of P-gp or MRP1 and the preoperative scintigraphy 
results or intraoperatively measured radioactivity. We confirmed the known correlation 
between 99mTc-Sestamibi imaging results and weight for hyperplastic glands. However 
the fact that neither weight nor the presence of P-gp or MRP1 contributed significantly 
to 99mTc-Sestamibi retention in adenomas in this study, implicates that other (unknown) 
factors played a role in the mechanism of uptake and retention in these adenomas. 
In other areas where P-gp expression has been extensively studied as potent 
cause of drug resistance that can be modulated by inhibitors in both in vitro and in 
vivo model systems, the clinical trials testing this paradigm have mostly failed.190 It 
is suggested that other transporters on the cell are co-expressed and compensate 
for the inhibition of P-gp. As expression of P-gp and MRP1 in parathyroids showed 
no correlation with clinical retention of Sestamibi in our study, we concluded there 
is insufficient evidence to explore the use of selective P-gp or MRP1 inhibitors for 
enhancing parathyroid imaging in the future.
Intraoperative PTH monitoring
The relatively short half-life of PTH (3-4 minutes), allows intraoperative monitoring 
after gland removal. It is widely used to predict surgical success in pHPT, however its 
role in surgery for sHPT and tHPT remains uncertain. In chapter 5 the clinical utility of 
ioPTH monitoring in the latter patients was evaluated. We performed a retrospective 
analysis of 50 patients with sHPT or tHPT undergoing total PTx with or without auto-
implantation. ioPTH samples were acquired after induction of anesthesia, at the 
moment of resection of the last enlarged parathyroid gland and 5, 10 and 15 minutes 
hereafter. Four different cut-off levels for amount of decrease of PTH as compared to 
baseline were evaluated to predict surgical success. At ten minutes a decrease in PTH 
>50% was seen in 98% of the patients after successful PTX and a decrease >80% in 
89%. Using 50% cut-off level at 10 or 15 minutes, sensitivity was 100%, specificity 17%, 
PPV 100%. Using 80% cut-off level at 10 minutes sensitivity was 91%, specificity 83%, 
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PPV 98%, negative predictive value (NPV) 56%. Using 80% cut-off level at 15 minutes 
sensitivity was 93%, specificity 67%, PPV 98%, NPV 57%. 
We concluded that ioPTH monitoring has a high PPV but low NPV. However 
considering the high pre-test probability for surgical cure after resection of four 
parathyroid glands, the potential benefit of ioPTH seems low. Moreover, there are 
multiple factors influencing ioPTH in sHPT as described in chapter 5. Therefore ioPTH 
results in sHPT may be difficult to interpret. We do not recommend standard use of 
ioPTH monitoring in sHPT. Its clinical utility in tHPT and reoperations must be further 
studied. 
Risk factors for refractory secondary hyperparathyroidism 
Secondary HPT is primarily managed by dietary and medical treatment. If despite 
medical treatment PTH, calcium and phosphate levels cannot be controlled, surgical 
treatment is indicated. Patients with a high risk for needing PTx in the long run, may 
benefit especially from early aggressive treatment. In chapter 6 early prognostic 
factors were identified for the development of refractory sHPT. Biochemical and 
treatment data were collected at the start and during the first year of dialysis in 202 
consecutive patients, who started RRT between August 1988 and August 1996 and 
met the inclusion criteria. These results were related to the need for PTx during long-
term follow-up. Univariate and multivariate analyses were used to identify risk factors 
for PTx during follow-up. In total 33 patients (16%) needed PTx after 52±23 months 
of RRT. Need for PTx was not different between patients undergoing hemodialysis 
and peritoneal dialysis, but was associated with parameters reflecting calcium and 
phosphate control at start and after 1 year of RRT. In a Cox multivariate model, serum 
parathyroid hormone [relative risk (RR): 1.02 per pmol/l; P<0.001], phosphate (RR: 1.107 
per 0.1 mmol/l; P = 0.002) and alkaline phosphatase (RR: 1.004 per U/l; P = 0.049) after 
1 year of RRT were independently associated with increased risk for PTx. Pre-dialysis 
correction of the calcium-phosphate metabolism as well as early control of phosphate 
during RRT are of major interest in the prevention of severe hyperparathyroidism. 
Patients at high risk may benefit from an aggressive approach in controlling calcium-
phosphate metabolism.
New medical therapies like calcium-free intestinal phosphate binders, lesser 
hypercalcemic vitamin D derivatives and calcimimetics have been introduced the last 
decade.191 Calcimimetics have proven most promising by reducing serum PTH, calcium 
and phosphate levels in dialysis patients in all stages of sHPT and decreasing the number 
of patients undergoing PTx.3,4,192 In a recent meta-analysis it appeared safe and effective 
for the treatment of tHPT as well.7 However, recently the results of a large prospective, 
multicentre, randomized, placebo-controlled trial (EVOLVE trial) have been published, 
showing no significant effect of cinacalcet on cardiovascular outcomes or death.4 The 
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study reported an insignificant 7% reduction in the risk of death or cardiovascular 
event in the unadjusted intention-to-treat analysis among patients using cinacalcet 
plus conventional therapy as compared to patients using a placebo plus conventional 
therapy.  High rates of treatment crossover and differences in baseline characteristics 
between the two groups, may explain this negative outcome.193 Moreover, a higher 
rate of neoplastic events was observed in the group receiving cinacalcet.  Considering 
the results of this trial it remains unclear whether cinacalcet can protect against 
cardiovascular events. Also its long-term efficacy, safety and long-term effects on other 
clinical outcomes have to be evaluated.4 One of the disadvantages of cinacalcet is the 
high cost. One study investigated the cost-effectiveness of administering cinacalcet 
in patients with refractory sHPT and demonstrated that cinacalcet is the more cost-
effective option for up to 7 months of treatment, after which time parathyroidectomy is 
the more cost-effective treatment modality.194 It may be concluded that calcimimetics 
are changing the treatment of sHPT and the risks for needing PTx, however PTx retains 
an important role in the treatment of refractory sHPT.
Parathyroid cancer
Parathyroid carcinoma is a rare malignancy and accounts for approximately 1% 
of patients with pHPT. In chapter 7 we reported the incidence, treatment, relapse-
free and disease-specific survival of 41 patients with parathyroid carcinoma in The 
Netherlands between 1989 and 2003. Ten-year recurrence-free and disease-specific 
survival rates were 71% and 79%, respectively. The most important factor of relapse 
was tumor involved resections margins and/or perioperative tumorspill (hazard ratio 
5.5; CI 1.1-27.1), as seen in 14 (34%) of the patients at initial resection. Efficacy of 
adjuvant radiotherapy in these patients was disappointing.
Commonly parathyroid carcinoma is diagnosed after surgery for pHPT, when the 
removed tumor shows malignant features at pathologic examination. Radical surgical 
resection is the only effective treatment modality, determining the prognosis of these 
patients. Therefore it is desirable to distinguish benign from malignant disease before 
surgery. The clinical features of patients with parathyroid carcinoma were recorded and 
compared with a cohort of patients with benign pHPT in the same period. Nineteen 
(46%) patients with a parathyroid carcinoma had a palpable neck mass.  Patients 
with carcinoma had significantly higher serum PTH and calcium levels compared 
with patients with pHPT. A PTH >3 times the upper normal limits was suspicious and 
levels more than 10 times carried a positive predictive value of 84% for carcinoma. 
These 3 factors in a patient with presumably benign pHPT should alert the clinician 
for parathyroid carcinoma. The rarity of this disease requires treatment by experienced 




During the last two decades a lot has changed in the surgical management of 
hyperparathyroidism. In pHPT main focus has been on enabling a focused approach 
with the use of improved preoperative imaging techniques and intraoperative tools 
like the gammaprobe and ioPTH monitoring. However multiglandular disease still 
cannot be identified with a very high accuracy with neither of these tools. 99mTc-
Sestamibi scintigraphy failed to identify multiglandular disease in 73% of the patients 
in a selected group of patients with pHPT and multiglandular disease. 195  Using ioPTH 
monitoring a success rate of 25-83% has been reported for identifying multiglandular 
disease during surgery.126,195 Norman et al, one of the founders of the focused approach, 
recently published their long–term results of 14,000 patients with pHPT undergoing 
primary parathyroidectomy.196 They observed that long-term failure rates were 11 times 
more likely for focused approach as compared to bilateral explorations. It is important 
to mention that Norman et al did not use ioPTH monitoring during their focused 
approach. Based on these results they have abandoned the focused approach and 
perform routinely bilateral explorations without extensive preoperative imaging and 
intraoperative use of gammaprobe or ioPTH monitoring. They point out that surgeon 
volume outweighs all other predictors of successful parathyroid surgery and stress 
the importance of thorough knowledge of parathyroid anatomy and embryology to 
perform successful bilateral explorations in day-care by minimal incision and in short 
operation time. Although their approach and results cannot be translated to our daily 
practice or those of many other clinicians, they give food for thought. Combining 
preoperative imaging with ioPTH monitoring justifies a focused approach.197 The 
greatest challenge remains the accurate identification of multiglandular disease in the 
coming decade. Development of improved criteria for interpreting ioPTH results 195 
and new imaging techniques like 4D-CT may improve results. However, surgical cure 
for pHPT and not focused approach should be the primary goal and long-term follow-
up is required.   
There have been several changes in the treatment of sHPT during the last decades. 
Especially the introduction of calcimimetics in the medical treatment shows good 
results. In the upcoming decade the long-term safety and effects on survival, vascular 
morbidity, bone symptoms and quality of life in patients have to be awaited and 
compared to parathyroidectomy. In the surgical treatment new preoperative imaging 
methods, intraoperative tools like the gammaprobe and ioPTH monitoring have been 
tried with variable success. There have been  no reports so far claiming improved 
success rates by these new tools. We have demonstrated use of the gammaprobe 
especially in confirming the resection of hyperactive parathyroid tissue, whereas 
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preoperative imaging before primary surgery and ioPTH monitoring had little added 
value in our opinion.  The overall success rate of parathyroidectomy for sHPT remains 
mainly dependent on the experience of the surgeon. Increasing surgeon volume by 
centralization should be one of the methods to improve quality and overall results. 
In December 2012 the Dutch foundation for oncologic cooperation (SONCOS), uniting 
clinicians out of the field of surgical oncology, medical oncology and radiotherapy, 
has published a quality framework for multidisciplinary oncological care in adults in 
the Netherlands. Now a minimum requirement of 20 parathyroidectomies yearly must 
be met per center. It is also required that preoperative scintigraphy/gammaprobe 
is available as well as ultrasonography and/or ioPTH monitoring.198 Centralization 
leading to higher hospital and  higher surgeon volume will improve the results of 
parathyroidectomies. However to develop and maintain high surgeon dedication 
and volume, more programs should be offered in the Netherlands for surgeons with 
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SAMENVATTING (voor de niet ingewijde)
Dit proefschrift “Diagnostic tools and risk identification in management of 
hyperparathyreoïdism”  beschrijft onderzoek naar de verschillende diagnostische 
middelen die gebruikt kunnen worden voor en tijdens een operatie aan de 
bijschildklieren. Daarnaast beschrijft het risicofactoren voor ernstige secundaire 
hyperparathyreoïdie en bijschildklier carcinoom. Hieronder volgt een korte 
samenvatting van de ziekte hyperparathyreoïdie, de behandeling en de in dit 
proefschrift gepresenteerde onderzoeken. 
Hyperparathyreoïdie is een overmatige productie van parathyreoïd hormoon 
(PTH) door te hard werkende bijschildklier(en). De meeste mensen hebben vier 
bijschildklieren die in de hals achter de schildklier zijn gelegen. Het zijn kleine klieren 
die lijken op een “kidney-bean” met een maximale normale afmeting van 50 millimeter. 
Tijdens een operatie kan het lastig zijn om ze te vinden of te herkennen. Circa 5-20% 
van de bijschildklieren is niet op de gebruikelijke locatie te vinden,  maar elders in het 
centrale deel van de hals of bovenste deel van de romp. Bij 5-6% van de mensen zijn 
er meer dan vier bijschildklieren aanwezig. 
Hyperparathyreoïdie is in bijna alle gevallen een goedaardige aandoening en er 
bestaan verschillende vormen. Primaire hyperparathyreoïdie (pHPT) ontstaat door een 
spontane afwijking in de bijschildklier; in 87% van de patiënten betreft het één klier, 
een adenoom, bij de overigen is er sprake van meerdere adenomen of hyperplasie. 
Secundaire hyperparathyreoïdie (sHPT) is veelal het gevolg van een langdurig gestoorde 
nierfunctie zoals bij dialyse patiënten. Door het nierfalen treden er verstoringen op in 
de calcium en fosfaatstofwisseling die de bijschildklieren voortdurend stimuleren tot 
meer PTH productie. Hierdoor ontstaat overgroei, hyperplasie, van alle bijschildklieren. 
Van tertiaire hyperparathyreoïdie (tHPT) wordt gesproken als patiënten na een 
niertransplantatie hyperparathyreoïdie blijven houden, ondanks herstel van de 
nierfunctie.  In zeer zeldzame gevallen wordt hyperparathyreoïdie veroorzaakt door 
een kwaadaardige tumor, het bijschildklier carcinoom.
PTH heeft als functie het calcium gehalte in het bloed op peil te houden.  Een te 
hoog PTH leidt tot het vasthouden van calcium door de nier, een verhoging van de 
opname van calcium door de darm en een verhoogde botafbraak. De meeste mensen 
met pHPT merken daar niets van en wordt pHPT bij toeval ontdekt. Ongeveer 20-30% 
van de mensen met pHPT hebben wel klachten die zich kunnen uiten als moeheid, 
spierzwakte, dorst, misselijkheid, braken, obstipatie, nierstenen, botpijn of botbreuken. 
Bij sHPT is een duidelijke relatie aangetoond tussen de verstoorde calcium- en 
fosfaathuishouding en vaatverkalkingen, hartziekten en mortaliteit. 
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De enige effectieve behandeling van pHPT is een parathyreoïdectomie (PTx), 
het operatief verwijderen van de overactieve bijschildklier(en). Indien middels 
preoperatieve beeldvorming één adenoom is aangetoond, kan veelal worden volstaan 
met een minimaal invasieve operatie. Bij sHPT en tHPT bestaat de behandeling 
uit dieetadviezen en medicijnen. Indien dit onvoldoende resultaat heeft, is een 
operatie noodzakelijk waarbij beide zijden van de hals worden geëxploreerd en 3,5 
klieren worden verwijderd of 4 met auto-implantatie (terugplaatsing van een halve 
bijschildklier in een spier voor beperkte restfunctie).  
Preoperatieve beeldvorming van bijschildklieren
Preoperatieve beeldvorming van de bijschildklieren is belangrijk diagnostisch middel 
voor de chirurg om een operatieplan te maken. Scintigrafie is het onderzoek van eerste 
keus. Hierbij wordt het radiofarmacon 99mTc-Sestamibi ingespoten in de bloedbaan van 
de patiënt en opgenomen in de schildklier en bijschildklieren. Na circa 1-2 uur spoelt 
het grotendeels uit de schildklier en blijft in de overactieve bijschildklier(en) zitten. 
Het radioactieve Technetium (Tc) zendt gammastraling uit die wordt opgevangen en 
weergegeven door een gammacamera. Er zijn verschillende scintigrafie technieken. 
Planaire scintigrafie bestaat uit 2-dimensionale statische beelden waarbij meestal 
een vroege en late opname met elkaar worden vergeleken. Door het uitwassen van 
99mTc-Sestamibi zullen op de late opname de overactieve bijschildkieren te zien zijn. 
Single photon emission computed tomography (SPECT) is een techniek waarbij een 
hoger contrast en een 3-dimensioneel beeld verkregen wordt. 123I-subtractie is een 
techniek waarbij de opname van jood in de schildklier wordt vergeleken met opname 
van Sestamibi in schildklier en bijschildklieren. Hiermee zijn laesies in de schildklier te 
onderscheiden die veel Sestamibi opnemen en daardoor een fout positieve uitslag 
veroorzaken.
 In hoofdstuk 2 zijn de resultaten beschreven van de toegevoegde waarde van 
SPECT en 123I-subtractie in aanvulling op planaire scintigrafie.  Hiervoor werden 
planaire scans van 111 patiënten beoordeeld, een aanvullende SPECT bij 64 patiënten 
en aanvullende 123I-subtractie beelden bij 17 patiënten.  Voor het aantonen van 
adenomen bij pHPT had planaire scintigrafie een sensitiviteit van 77%. SPECT 
verbeterde dit resultaat niet, maar wel de interpretatie door de nucleair geneeskundige 
waardoor het operatieplan bij 21% van de mensen ten goede veranderde. Door het 
3-dimensionele beeld van SPECT konden klieren die niet op de gebruikelijke plaats in 
de hals lagen, beter worden geïdentificeerd. 123I-subtractie was enigszins behulpzaam 
bij enkele patiënten bij wie planaire scintigrafie en SPECT niets lieten zien, maar gaf 
meer fout positieve uitslagen. Voor het aantonen van hyperplastische klieren bij sHPT 
had planaire scintigrafie een sensitiviteit van 47%. SPECT en 123I-subtractie gaven geen 
verbetering van deze resultaten.
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Geconcludeerd is dat SPECT een waardevolle toevoeging is op planaire 99mTc-
Sestamibi scintigrafie voor het lokaliseren van adenomen bij pHPT. 123I-subtractie heeft 
mogelijk toegevoegde waarde als andere technieken geen resultaat opleveren. Gezien 
de lage sensitiviteit voor hyperplastische klieren  heeft preoperatieve scintigrafie bij 
patiënten met sHPT weinig waarde. In het geval van een reoperatie bij sHPT is uit de 
literatuur bekend dat preoperatieve lokalisatie wel zinvol is. 
Parathyreoïdectomie met behulp van de gammaprobe
De gammaprobe is een kleine penvormige gammastralingdetector dat als diagnostisch 
middel tijdens de operatie gebruikt kan worden nadat de patiënt een injectie met 
99mTc-Sestamibi heeft gehad. In het geval van pHPT is aangetoond dat de probe de 
chirurg kan helpen bij het vinden van het adenoom en na resectie kan bevestigen dat 
het gaat om een adenoom als de gemeten radioactiviteit van het verwijderde weefsel 
>20% bedraagt ten opzichte van de activiteit in het wondgebied. Over de toepassing 
van de gammaprobe bij sHPT is onvoldoende bekend. 
In hoofdstuk 3 zijn de resultaten gepresenteerd van onderzoek naar de 
bruikbaarheid van de probe bij 29 patiënten met sHPT of tHPT. De probe hielp bij het 
identificeren van slechts 13% van de bijschildklieren. De probe had een sensitiviteit van 
97% en een specificiteit van 92% voor het vaststellen van een hyperplastische klier na 
resectie volgens de 20%-regel. Geconcludeerd is dat de gammaprobe voor sHPT een 
beperkte rol heeft in het sturen van de chirurg tijdens de operatie, maar behulpzaam is 
in het bevestigen van de resectie van een hyperplastische klier. De probe kan derhalve 
gebruikt worden in de plaats van vriescoupe analyse tijdens de operatie.
 
Kunnen de resultaten van 99mTc-Sestamibi scintigrafie worden verbeterd?
99mTc-Sestamibi is het meest gebruikte radiofarmacon voor bijschildklier scintigrafie. 
Het exacte mechanisme van stapeling in de bijschildklier is onbekend. In hoofdstuk 
4 is onderzoek gepresenteerd naar de rol van P-glycoproteine (P-gp) en multidrug 
resistance-associated protein 1 (MRP1) hierin. Beide zijn transmembrane eiwitten 
die in staat zijn om 99mTc-Sestamibi de cel uit te pompen. Als er een belangrijke rol 
is weggelegd voor deze eiwitten in de stapeling van 99mTc-Sestamibi, dan zou het 
resultaat van scintigrafie kunnen worden verbeterd door medicijnen die deze eiwitten 
blokkeren.
Er zijn 33 patiënten onderzocht die PTx met de gammaprobe ondergingen. In 
totaal werden 23 adenomen, 36 hyperplastische klieren en 4 normale bijschildklieren 
verwijderd. Na routine weefselbewerking werden immunuhistochemische kleuringen 
op P-gp en MRP1 uitgevoerd. De mate van aankleuring werd weergegeven in een 
score en vergeleken met preoperatieve scintigrafie resultaten, histologie, gewicht 
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en peroperatief gemeten radioactiviteit van gereseceerde klieren. P-gp kleuring was 
positief in 91%  van de adenomen en 100% van de hyperplastische klieren. MRP1 
kleuring was positief in 22% van de adenomen en 61% van de hyperplastische 
klieren. Er werd geen verband gevonden tussen de expressie van P-gp of MRP1 en 
preoperatieve scintigrafie resultaten of peroperatief gemeten radioactiviteit. In het 
geval van hyperplastische klieren werd de uit de literatuur bekende relatie tussen 
gewicht en 99mTc-Sestamibi opname bevestigd. Bij adenomen was dit niet het geval. 
Dit betekent dat andere vooralsnog onbekende factoren een rol spelen in de stapeling 
van 99mTc-Sestamibi in de bijschildklier. 
Peroperatieve PTH monitoring
PTH monitoring wordt gebruikt als diagnostisch middels tijdens de operatie om 
te bekijken of één of meerdere bijschildklieren zijn aangedaan bij pHPT. Dit is 
wenselijk omdat bij preoperatieve beeldvorming een tweede adenoom of meerdere 
hyperactieve bijschildklieren kunnen worden gemist. De korte halfwaarde tijd van 
PTH (3-4 minuten) maakt het mogelijk om veranderingen in productie door de 
bijschildklier(en) tijdens de operatie te vervolgen. Een snelle PTH daling na resectie 
van een adenoom  toont aan dat de overige klieren niet aangedaan zijn en de operatie 
hiermee geslaagd is. Op deze wijze kan met een minimaal invasieve ingreep worden 
volstaan zonder de andere klieren peroperatief in beeld te brengen. 
De klinische bruikbaarheid van peroperatieve PTH monitoring tijdens PTx voor 
sHPT is onduidelijk. In hoofdstuk 5 zijn de resultaten gepresenteerd van peroperatieve 
PTH monitoring bij 50 patiënten met sHPT of tHPT. Tijdens de operatie werden PTH 
monsters verzameld. Er werden verschillende grenzen gehanteerd voor de mate van 
PTH daling na excisie van de laatste klier voor het voorspellen van chirurgisch succes. 
De operatie was succesvol bij 47 (94%) patiënten. Tien minuten na excisie van de laatste 
klier was bij 98% van de patiënten sprake van een PTH daling >50% in vergelijking met 
de PTH waarde voor incisie en in 89% was er sprake van een daling >80%.  Indien een 
grens van 50% daling na 10 of 15 minuten werd gehanteerd, bedroeg de sensitiviteit 
100%, specificiteit 17% en positief voorspellende waarde 100%. Indien een grens van 
80% daling na 10 minuten werd gehanteerd bedroeg de sensitiviteit 91%, specificiteit 
83%, positief voorspellende waarde 98% en negatief voorspellende waarde 56%. 
Indien een grens van 80% daling na 15 minuten werd gehanteerd, bedroegen deze 
waarden 93%, 67%, 95% en 57% respectievelijk. 
Geconcludeerd is dat de peroperatieve PTH monitoring in sHPT een hoge positief 
voorspellende waarde heeft, maar een lage negatief voorspellende waarde. Door 
de hoge waarschijnlijkheid van een positieve uitslag na het verwijderen van vier 
bijschildklieren, heeft de peroperatieve PTH monitoring weinig toegevoegde waarde. 
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Daarnaast zijn er bij sHPT meerdere factoren die tijdens de operatie van invloed zijn 
op de uitslagen van de PTH waarden, waardoor de interpretatie lastig kan zijn. Daarom 
raden wij het gebruik ervan tijdens PTx voor sHPT af. 
Risico factoren voor secundaire hyperparathyreoïdie
Secundaire hyperparathyreoïdie bij patiënten met chronische nierfunctie stoornis 
wordt primair behandeld middels dieet en medicijnen.  Indien desondanks ernstige 
sHPT ontstaat, is een operatieve verwijdering van de bijschildklieren noodzakelijk. 
Patiënten die een verhoogd risico lopen op deze operatie hebben wellicht baat bij 
een agressievere behandeling met medicijnen in een vroeg stadium. In hoofdstuk 6 is 
onderzoek gepresenteerd naar factoren bij dialyse patiënten die een verhoogd risico 
op PTx in de toekomst voorspelden. De gegevens van 202 patiënten tijdens de start 
en gedurende het eerste jaar van dialyse werden verzameld en gerelateerd aan de 
kans op PTx gedurende follow-up. Bij 33 patiënten (16%) was een PTx noodzakelijk na 
gemiddeld 52dialyse maanden. Het bleek dat verhoogd serum PTH, fosfaat en alkalisch 
fosfatase 1 jaar na start van dialyse de beste voorspellers waren voor een verhoogd 
risico op PTx in de toekomst. Geconcludeerd is dat de correctie van de calcium- en 
fosfaat huishouding zowel voor als tijdens het begin van dialyse van groot belang is 
voor de preventie van ernstige secundaire hyperparathyreoïdie. Patiënten met een 
verhoogd risico op hierop kunnen het best geïdentificeerd worden op basis van het 
PTH, fosfaat en alkalisch fosfatase 1 jaar na start van dialyse.
Parathyreoïd carcinoom
Parathyreoïd carcinoom is een zeldzame kwaadaardige aandoening die bij ongeveer 
1% van de mensen met pHPT voorkomt.  In hoofdstuk 7 is de incidentie, behandeling 
en overleving beschreven van 41 patiënten die tussen 1989 en 2003 in Nederland 
werden gediagnosticeerd met parathyreoïd carcinoom. De tien jaars ziektespecifieke 
overleving betrof 79% bij deze patiënten en 71% had geen tekenen van een recidief  in 
deze periode. De belangrijkste factor gerelateerd aan een recidief was tumor positieve 
resectie vlakken en/of peroperatieve tumor spil. Dit deed zich voor bij 14 patiënten 
(34%). Het resultaat van aanvullende bestraling was teleurstellend. 
Meestal wordt parathyreoïd carcinoom pas vastgesteld na de operatie door 
middel van weefselonderzoek door de patholoog. Aangezien radicale resectie de 
enige effectieve behandeling is en de prognose bepaalt, is het wenselijk reeds voor 
de operatie goedaardige pHPT te onderscheiden van parathyreoïd carcinoom. 
Derhalve zijn de klinische kenmerken van patiënten met parathyreoïd carcinoom 
vergeleken met kenmerken van patiënten met pHPT in dezelfde periode. In totaal 19 
(46%) patiënten met parathyreoïd carcinoom hadden een palpabele tumor in de hals. 
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Daarnaast hadden zij een significant hoger serum PTH en calcium voorafgaand aan de 
operatie. Serum PTH driemaal hoger dan normaal was verdacht voor carcinoom. Indien 
het serum PTH tien maal hoger was dan normaal, bedroeg de positief voorspellende 
waarde 84% voor een parathyreoïd carcinoom. Geconcludeerd is dat een palpabele 
massa in de nek, serum PTH waarde drie maal hoger dan normaal en ernstige 
hypercalciëmie kunnen wijzen op een parathyreoïd carcinoom. Parathyreoïdectomie 
bij een dergelijke patiënt dient bij voorkeur in een gespecialiseerd centrum uitgevoerd 
te worden. 
De toekomst
Nieuwe technieken zoals verbeterde preoperatieve beeldvorming, peroperatieve 
gammaprobe en PTH monitoring hebben minimaal invasieve parathyreoïdectomie bij 
pHPT mogelijk gemaakt.  Echter zelfs met de modernste technieken blijkt het moeilijk 
om alle patiënten bij wie meerdere bijschildklieren zijn aangedaan te onderscheiden. 
Dit blijft daarom de grootste uitdaging in de toekomst.  Nieuwe en verbeterde 
beeldvorming en verbeterde methode en interpretatie van peroperatieve PTH 
waarden kunnen hieraan bijdragen. Hierbij moet voorop staan dat minimaal invasieve 
techniek een middel is en niet een doel  op zich. Daarnaast moeten de lange termijn 
resultaten van minimaal invasieve operaties worden beoordeeld.
De behandeling van sHPT middels medicijnen is het afgelopen decennium 
veranderd.  Vooral de introductie van calcimimetica heeft veelbelovende resultaten 
opgeleverd. In het komende decennium zullen onder andere de veiligheid van dit 
medicijn op de lange termijn en de effecten op overleving en hart- en vaatziekten 
moeten worden geëvalueerd en vergeleken met de chirurgische behandeling. De 
chirurgische behandeling van sHPT is daarentegen niet veel veranderd. Het is niet 
aangetoond dat de gammaprobe of intra-operatieve PTH monitoring het succes van 
de chirurgische behandeling kunnen verbeteren. Het succes van de behandeling 
blijft hoofdzakelijk afhankelijk van de ervaring van de chirurg. Centralisatie die leidt 
tot een hoger volume per ziekenhuis en per chirurg,  zal de operatie resultaten bij 
hyperparathyreoïdie ten goede komen. Het recent vastgestelde minimum van 20 
parathyreoïdectomieën per ziekenhuis per jaar is een stap in de goede richting.  
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Zo, het zit er bijna op. Het heeft even geduurd, maar het resultaat telt. Het heeft mij rijke 
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aan een of meerdere hoofdstukken uit dit boekje. Graag wil ik iedereen daarvoor 
ontzettend bedanken, een aantal mensen wil ik in het bijzonder noemen.
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kliniek zijn mij goed bijgebleven. Dank hiervoor.
Dr. P.L. Jager. Beste Piet, jij was voor mij een grote steun tijdens mijn eerste stappen als 
onderzoeker. Door jou ben ik in de grijze stippen van de scans de bijschildklieren gaan 
zien. Hoewel het inmiddels een tijdje geleden is, heb ik goede herinneringen aan de 
gezamenlijke beoordelingen met een bakje koffie en een lach.  Dank hiervoor.
Dr. A.H. Brouwers. Beste Adrienne, na het vertrek van Piet kwam jij op de voorgrond. Met 
jou was het altijd prettig en harmonieus samenwerken.  Dank voor je bereidheid om mijn 
copromotor te zijn.
Prof. dr. H. Hollema. Beste Harry, door jou heb ik de bijschildklier van heel dichtbij leren 
kennen en konden de P-gp en MRP1 kleuringen op een snelle en efficiënte wijze worden 
beoordeeld. Bedankt voor je bijdrage. 
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Dr. A.C. Muller Kobold. Beste Anneke, bedankt voor je snelle beoordelingen en kundige 
adviezen ten aanzien van hoofdstuk 5, en dat ik je zelfs op de vroege kerstavond mocht 
storen voor een korte vraag. 
Dr. M. Schaapveld. Beste Michael, vanuit het IKNO heb jij een grote bijdrage geleverd 
aan de totstandkoming van hoofdstuk 7. Daarnaast is jouw uitleg over menig statistiek 
verhelderend geweest. Dank hiervoor.
Beste medeauteurs. Dank voor de prettige samenwerking bij de totstandkoming van 
de verschillende hoofdstukken beschreven in dit boekje.
Alle medewerkers van de afdeling Nucleaire Geneeskunde. Naast de zeer prettige 
samenwerking voelde jullie oprechte persoonlijke belangstelling voor mij als een 
warme deken.  In het bijzonder noem ik Clara Lemstra. Clara, jij bent het afgelopen 
decennium een zeer enthousiaste, deskundige en gedreven verbinding tussen de 
chirurgische en nucleaire afdeling gebleken. Daarnaast was je voor mij een persoonlijke 
steun.  Hiervoor mijn dank en ik wens je na het afronden van je opleiding tot physician-
assistant in februari heel veel succes toe.
Collega-onderzoekers met wie ik jaren terug het wel en wee van het bestaan als 
onderzoeker mocht delen: Wim Dieperink, Joke Fleer,  Martijn Lutke Holzik, Esther 
Bastiaannet, Kirsten Kuizenga, Rudy Komdeur, Erik van Westreenen, Tjeerd Boelstra, 
Anne Brecht Francken, Annemarie Nijboer, Marit Tuinman. Eindelijk kan ik ook op deze 
wijze bedankt tegen jullie zeggen voor de waardevolle en gezellige koffie momenten. 
Er is voor ons allemaal inmiddels veel veranderd, maar ik hoop jullie graag weer als 
collega’s elders te ontmoeten.
Verpleegkundigen van de verpleegafdeling chirurgische oncologie, operatieassistenten 
van het operatie centrum en laboranten van de diverse laboratoria, bedank ik voor de 
fijne samenwerking. 
Voor alles dat ik heb mogen leren tijdens mijn opleiding tot chirurg en de fijne 
samenwerking, wil ik mijn opleiders Dr. W.J.H.J. Meijerink, Prof. dr. J.P.E.N Pierie, Prof. 
dr. H.J. ten Duis, Dr. R.J. van Ginkel, Prof. dr. E. Heineman, de chirurgen en collega-




Lieve vrienden en buren. Hoewel jullie niet inhoudelijk hebben bijgedragen aan 
dit proefschrift, is jullie inbreng buiten het werk onontbeerlijk. Bedankt voor jullie 
vriendschap, steun en belangstelling. 
Ir. F.D. Jorna en dr. R.C. Niessen. Bedankt dat jullie mijn paranimfen willen zijn. Lieve Frank, 
als grote broer hield je vroeger mijn hand soms vast en ik ben trots dat je dat op deze dag 
ook wilt doen. Lieve Renée, hoewel ik je pas in de collegebanken heb leren kennen, gaat 
onze geschiedenis terug tot onze wiegen die naast elkaar stonden in het ziekenhuis. Veel
lol hebben we gehad in onze studietijd en elke keer als we elkaar opzoeken voelt het als 
vanouds. Dat je mij ook deze dag wilt vergezellen en bijstaan, is hierop een mooi vervolg. 
Beste James, helaas kan je er niet bij zijn als paranimf tijdens mijn verdediging. Jouw 
inbreng binnen ons assistentenhok en ongezouten mening heb ik altijd goed kunnen 
waarderen. Bedankt voor je collegialiteit en vriendschap.
Leave Heit en Mem, Lieve Pa en Ma, en familie. Hoewel jullie dit project geruime tijd 
vanaf een afstand hebben gadegeslagen, bleef jullie belangstelling overeind. Bedankt 
voor de steun op alle fronten op de momenten dat het nodig was.
Lieve Rutger, zonder jouw onvoorwaardelijke steun en liefde zou ik mijn opleiding en 
dit proefschrift niet hebben kunnen voltooien. Ik beloof je dat tijdens de eerst volgende 
vakantie de computer thuis blijft! Bedankt dat je er voor mij bent! 




   Dankwoord





Ciska werd geboren op 20 april 1976 te Leeuwarden. Samen 
met haar twee broers groeide zij op op de boerderij in het 
hart van Friesland. Zij bezocht de lagere school in Mantgum. 
Daarna stapte Ciska dagelijks om 7 uur met plezier op de 
fiets  naar het Stedelijk Gymnasium te Leeuwarden, waar zij 
in 1994 haar diploma haalde. Nadien trok zij een jaar lang 
rond in Australië, Nieuw-Zeeland en Indonesië terwijl ze 
onderweg haar eigen kost verdiende. In de zomer van 1995 
kwam zij terug om met de studie geneeskunde te starten.  
Tijdens haar studietijd was Ciska naast haar opleiding actief binnen de Groninger 
Studenten Alpen Club. Zij beleefde veel plezier in het sporten, commissie 
werkzaamheden, klimweekenden en bergsport vakanties met clubgenoten. Hier 
leerde zij haar man Rutger kennen.  Studie geneeskunde bleek een goede keus en 
ontwikkelingen hierbinnen lieten haar niet koud. Ze was actief in de commissie ter 
behartiging van de studentenbelangen (Promed), de Co-raad en student-lid van de 
projectgroep Curriculum Ontwikkeling. Ze verrichte haar wetenschappelijke stage op 
het gebied van neuro-immunlologie aan de Bar Ilan University in Tel Aviv. Tijdens haar 
coschappen in het MCL te Leeuwarden ontwikkelde zij haar belangstelling voor de 
chirurgie en in het bijzonder de hoofd-hals chirurgie. In 2001  behaalde ze cum laude 
haar artsexamen.
Na haar studie kwam Ciska in contact met Prof. dr. J.T.M. Plukker voor wie zij het 
doelmatigheidsproject ‘Effectiveness of gammaprobe and intraoperative PTH 
measurement in the surgical treatment of hyperparathyroidism’ uitvoerde. In deze 
periode werd de basis gelegd voor dit proefschrift. Naast haar werk richtte ze zich 
op atletiek en is begonnen met skiën en hockey. Ze deed klinische ervaring op als 
arts-assistent op de Chirurgische Intensive Care van het UMCG, waarna ze werd 
aangenomen voor de opleiding Heelkunde in 2005. 
De eerste vier jaren van haar opleiding voltooide ze in het MCL te Leeuwarden. In 
dezelfde periode kreeg zij samen met Rutger twee kinderen, Hidde en Myrte. De 
combinatie van reizen, werken, leren en voor de kinderen zorgen, ging haar niet 
in de koude kleren zitten. Het wetenschappelijke werk kwam hierdoor op een laag 
pitje te staan. In 2010 vervolgde ze haar opleiding in het UMCG met het laatste jaar 
differentiatie in de gastro-intestinale en oncologische chirurgie. In deze periode werd 
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hun zoon Rinze geboren.  In oktober 2012 rondde ze haar opleiding af. In de twee 
maanden hierna werd dit proefschrift voltooid.  
Ciska en Rutger wonen momenteel in Zuidhorn met hun drie kinderen. Rutger in’t Hof 
is werkzaam als Manager Finance bij Friesland Campina in Wolvega en Amersfoort. 
Trimhockey, hardlopen en skiën doet ze nog graag. Op het moment van schrijven, is 
Ciska op zoek naar een geschikte baan waarbij de voorkeur uitgaat naar een fellowship 
binnen de gastro-intestinale en oncologische chirurgie dan wel endocriene chirurgie.
